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ABSTRACT 
HOLLY MCCLAIN BURKE: CONTRACEPTIVE CONTINUATION IN KENYA 
(Under the direction of Carolyn Tucker Halpern) 
 
Contraceptive discontinuation is high in Kenya—a quarter of family planning (FP) 
users discontinue within 12 months, despite having FP needs.  The purpose of this 
dissertation was to provide the foundation for interpretation of the findings of a four-year, 
quasi-experimental intervention study being conducted to encourage the continued use of 
contraceptives by developing, implementing and evaluating a communication campaign 
intended to increase continuation rates among contraceptive injectable users in Nyando 
District, Kenya.  The pre-intervention research in this dissertation is presented in two papers.   
For the first paper, fourteen focus group discussion (FGDs) were conducted in 
Nyando District among current contraceptive injectable users and their salient references, 
people who influence women’s use and discontinuation of contraception.  The purpose of 
the FGDs was to understand why women discontinue using contraceptives. For the second 
paper, continuation rates were measured in two districts in western Kenya before 
implementing a campaign to increase contraceptive continuation.  Prospective data were 
collected over 9-months to:  (a) describe factors which predict occurrence and timing of 
contraceptive discontinuation among first-time contraceptive injectable users, and (b) 
determine if rates and predictors of discontinuation differ between districts.  The second 
study incorporated novel time-dependent attitudinal and motivational factors. 
 In the first paper, discontinuation occurred for logistical, social and medical reasons.  
Common reasons for discontinuation included side effects, husbands’ opposition, provider 
and/or clinic restrictions, misconceptions about injectables, stock outs, and lack of cash to 
purchase contraceptives or pay for FP services. 
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The following factors predicted discontinuation in the second paper: side effects or 
health concerns, nervousness about using contraception, no previous use of modern FP, 
unmarried at study enrollment, preferring more privacy during FP appointment, and paying 
more for FP services.  Associations between predictors and discontinuation differed 
between the districts, as did rates of discontinuation.   
The findings from both papers highlight the importance of side effects and health 
concerns on premature discontinuation of contraception suggesting that FP services more 
strongly address these topics.  Both studies also indicate that interventions aimed at 
increasing continuation be tailored to address community-specific concerns.  Results are 
used to suggest intervention points for increasing continuation of FP in western Kenya. 
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CHAPTER 1. Introduction 
Family planning campaigns have historically and successfully targeted women not 
using contraception with messages describing the advantages of preventing unwanted 
pregnancies and method-specific information.  While these campaigns are warranted, we 
appear to have forgotten about women after they agree to adopt a method.  For 
contraceptive methods to work effectively women must continue using the method over time.   
Four categories of method discontinuation are: method failure, switching, abandonment by 
users not in need (due to desire for pregnancy or reduced risk of pregnancy), and 
abandonment by users in need (i.e., those at risk of unintended pregnancy). It is this last 
type, abandonment of users in need, which is the focus of this dissertation. 
Discontinuation may lead to unintended pregnancy and the multitude of health, 
economic and social consequences that it entails.  The true public health impact of 
contraception (improved maternal and infant health, quality of life and economic well-being) 
will not be realized until all women who want to prevent pregnancies are using their method 
of choice continuously and effectively. 
Despite increases in contraceptive prevalence over the past decades, 
discontinuation rates are high among women in the developing world.  According to the 
2003 Kenya Demographic and Health Survey (DHS), 33% of married women were using a 
modern method, but 25% of all contraception users discontinued within 12 months of 
beginning use, despite still being in need of family planning (not due to desire for pregnancy 
or reduced risk of pregnancy).  
Interventions focused on increasing continuation rates are sparse.  As a starting 
point, it is logical to look at interventions that have increased contraception adoption.
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Communication campaigns have been successful in increasing contraceptive adoption 
around the world, including Kenya.  A campaign to increase contraceptive continuation in 
Kenya may serve as a model for other African countries.  In response to the need for 
effective interventions to increase continuation, a four-year prospective, quasi-experimental 
study is being conducted that is developing, implementing and evaluating a communication 
campaign intended to increase continuation rates among contraceptive injectable users in 
Nyando District, Kenya.  This dissertation focuses on the developmental work and baseline 
information that is needed to interpret the findings from the evaluation of the intervention 
study (expected in 2010).   
This dissertation uses data from the pre-intervention study to address the following 
specific aims: 
(1) Using qualitative methods, to identify reasons why women in Nyando District 
Kenya discontinue using contraceptive injectables as seen from the perspectives of 
current users and their salient referents; 
(2) To describe the factors which predict the occurrence and timing of contraceptive 
discontinuation among first-time contraceptive injectable users still in need of family 
planning in the treatment (Nyando District) and comparison (Mumias District) sites 
before implementation of the communication campaign; and  
(3) To determine if the rates and predictors of discontinuation differ between the 
study districts before implementation of the communication campaign.  
 
The achievement of these aims will advance our understanding of contraceptive 
continuation behavior in western Kenya, which can be used to inform interventions designed 
to increase continuation rates in the region.  This dissertation will also contribute valuable 
information to guide interpretation and recommendations generated from evaluation of the 
intervention. 
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Background 
Discontinuation may lead to unintended pregnancy  
Unintended pregnancy is defined as a pregnancy that is unwanted (occurred when 
no children or no more children were desired) or mistimed (occurred earlier than desired).[1]  
Women who have unintended pregnancies and their resulting children are more likely to 
encounter negative health, social, and economic outcomes.[1]  Women who have 
unintended pregnancies are more likely to be physically abused during the pregnancy [2], 
and experience lower levels of psychological well-being [3], lower educational attainment, 
increased poverty, and increased welfare dependency.[1, 4]  Infants born to women who 
report the pregnancy was unwanted are more likely to die during the first year of life and be 
abused, and less likely to receive resources required for healthy development.[1]   
Another consequence of unintended pregnancy is abortion.  In the US, data from the 
National Survey of Family Growth demonstrated over half of unintended pregnancies in 
1994 ended in abortion.[5]  Despite being safe in the US, in settings were abortion is illegal 
women face greater risk of morbidity and mortality from incomplete or septic abortions, as 
well as legal ramifications and stigma associated with the procedure.[1] 
Unintended pregnancy may occur for a number of reasons, including nonuse of 
contraceptives, failure to use contraceptives consistently and correctly, and method failure 
among those using a method correctly.[4]  Discontinuation may explain why women in 
countries with relatively high contraceptive prevalence are experiencing unintended 
pregnancies, [4, 6] given that the level of current use and demographic impact of 
contraception becomes increasingly more dependent on continuation as contraceptive 
adoption increases.[6-9]  
Hormonal contraceptives, including contraceptive injectables, are the most popular 
reversible methods of family planning in the world and in Kenya. [10] However, these 
methods do not approach their theoretical effectiveness due to their relatively high 
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discontinuation rates.  For example, a study using data from Demographic and Health 
Surveys (DHS) from 15 developing countries found that 10-34% of users became pregnant 
within three months of discontinuing a modern method.[6]  The authors concluded (p 138), 
“…as fertility declines, family planning programs would profit from a shift in emphasis from 
providing methods to new clients towards providing services, such as counseling, that may 
help reduce discontinuation rates.”[6]  Discontinuation is a common problem.[11, 12]  In a 
six-country study, conducted in Morocco, Tunisia, Egypt, Ecuador, Indonesia, and Thailand, 
over one-fifth of couples who had not intended to become pregnant or were pregnant due to 
method failure had discontinued their method within one year of acceptance.[11] 
Contraceptive use and discontinuation in Kenya 
In the late 1970s Kenya had the highest fertility rate in the world.[13]  Through public 
health efforts the country has since experienced one of the most dramatic fertility declines.  
The decrease in the fertility rate has been attributed to the increase in contraceptive 
prevalence.  Indeed, contraceptive use of any method among married women has increased 
from 17% in 1984 to 33% in 1993 to 39% in 1998 and 41% in 2003.[14]  The predominant 
method used in 2003 was injectables (15% of currently married women), followed by the pill 
(8%).  Other methods used among currently married women included periodic abstinence 
(7%), female sterilization (5%), IUD (3%), implants (2%), male condom (1%), folk methods 
(<1%) and withdrawal (<1%).  Changes in the method mix demonstrate that the prevalence 
of injectable use has increased while the use of the pill has decreased.  In relation to other 
countries in east and southern Africa, Kenya has the third highest level of contraceptive use, 
exceeded only by Zimbabwe and South Africa. 
Despite the fact that 33% of currently married women in Kenya reported using a 
modern method in 2003, 20% of births were reported as unwanted and 25% were reported 
as mistimed that year among this group.[14]  Although, the overall proportion of births 
reported mistimed or unwanted has not changed since 1998, the proportion reported 
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unwanted has increased from 1998 to 2003 with a comparable reduction in the proportion 
reported mistimed. 
Contraceptive discontinuation in Kenya has increased since the 1998 DHS and the 
increase has been attributed to the relatively high discontinuation rates for pills and 
injectables. [14,15] Despite the popularity of the method, 21% of injectable users in Kenya 
discontinue use of the method within 12 months of starting, despite still having family 
planning needs (i.e., discontinuation is not due to desire for pregancy or reduced risk to 
pregnancy). [14] 
Contraceptive injectables 
Contraceptive injectables are highly effective, reversible methods of pregnancy 
prevention and are in the first tier of contraceptive effectiveness.[16, 17]  Two types of 
injectables are progestin-only and combination injectables, which include progestin and 
estrogen.  The most common type of injectable is the progestin-only formulation called 
depot medroxyprogestrone acetate (DMPA), and it is the focus of this dissertation.[18]  
DMPA is given by an intramuscular injection every three months and works primarily by 
stopping ovulation.[18] Another type of progestin-only injectable is norethindrone enanthate 
(NET-EN), which is administered every two months.  Both DMPA and NET-EN have failure 
rates in the range of 0.4 per 100 woman-years according to a multicenter trial conducted by 
the World Health Organization (WHO).[19]  Other sources cite a first year, perfect use failure 
rate of 0.3%.[16] Actual use of these methods yields a failure rate of around 3% over the 
first 12 months of use.[16, 20]  A new formulation of DMPA for subcutaneous injection has 
been approved for use in the United States and United Kingdom, but is currently not 
available in developing countries.[18] 
Injectables are characterized by active use and passive discontinuation.  In other 
words, women have to do something for the method to be effective, i.e., return to the clinic 
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every three months for an injection.  Discontinuation of injectables is passive, meaning all 
women have to do to discontinue is not return for their next injection.  This is in contrast to 
methods which require passive use, active discontinuation like implants and IUDs—once 
inserted women do not have to do anything for the method to be effective.  However, if they 
want to discontinue using implants or IUDs women must actively seek out a provider who 
can remove it.  This distinction has implications for studying and influencing discontinuation 
behavior. 
Side effects are the predominant determinant of discontinuation of injectables 
Family planning service-related factors, including quality of care, have been thought 
to be associated with contraceptive discontinuation.[8]  However, studies of quality of care 
have not been able to show large effects on discontinuation rates.[21-24]  Consistent 
determinants of discontinuation include:  type of method used, side effects, age (younger 
women are more likely to discontinue than older women), fewer number of living children, 
fertility intentions (women wanting to increase space between their children are more likely 
to discontinue compared with women who have completed childbearing), and a change in 
marital status (women who experience a change in martial status are more likely to 
discontinue).[12]  Surprisingly, discontinuation appears to be less consistently associated 
with the number of methods available [21], socio-economic factors including education [7, 
11, 12], urban-rural residence [11], husband’s disapproval [25], or cost or lack of access to 
the method [7, 21]. 
According to the 2003 DHS conducted in Kenya, side effects are the most common 
reason reported for discontinuation. [14] This finding is predominantly due to side effects 
associated with pills and injectables, the most commonly used methods.  Among the 
discontinuations reported in the five years before the 2003 DHS, the percentage that were 
attributed to side effects increased from 20% in 1998 to 25% in 2003.  Furthermore, in 2003 
13% of currently married women who were not currently using a method reported that they 
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did not intend to use a method in the future because of fear of side effects.  The proportion 
climbs to 20% for those women under 30 years of age. 
The study of 15 developing countries discussed above found that hormonal methods, 
including injectables, were more likely to be discontinued due to side effects or health 
concerns.[21]  Excluding Zimbabwe, which has a relatively low discontinuation rate for this 
method, discontinuation of injectables due to side effects ranged from 15% to 37% among 
the fourteen other countries surveyed. 
The term "side effects" may be thought to encompass the following:  clinical side 
effects, clinical health concerns, and fears about contraceptive injectables.   Clinical side 
effects and health concerns are those which have been evaluated through research studies 
and are found in the medical literature on injectables.  The last category, fears about 
injectables, includes those side effects or health concerns women fear or worry about, yet 
are not founded in the medical literature.  Some may call these fears "myths," however this 
label should not minimize the enormous influence they may have on discontinuation.  Given 
the important role side effects, health concerns, and fears play in discontinuation they are 
examined more closely in the following sections. 
Clinical side effects of DMPA injectables 
The clinical side effects of DMPA include: 
• Changes in menstrual bleeding (light spotting at first, amenorrhea especially after the 
first year of use, or rarely, heavy bleeding);[18, 26, 27] 
• Weight gain; [18, 26, 27] 
• Delayed return to fertility (about four months longer than women using combined oral 
contraceptives); [18, 26, 27] 
• Headaches[18, 26, 27] 
• Dizziness[18, 27] 
• Mood changes[18, 26, 27] 
• Abdominal bloating and discomfort[18] 
• Reduced libido[18, 26, 27] 
• Breast tenderness[26] 
• Nausea[26, 27] 
• Hair loss[26] 
• Acne[26] 
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Menstrual changes 
The most common reason for discontinuation of hormonal methods is disruption of 
the menstrual cycle.[19] Menstrual irregularity (increased number of days of light bleeding or 
amenorrhea) is very common among injectable users.[16] Amenorrhea increases over time 
among DMPA users.  Only 30% of DMPA users have regular cycles in the first year and this 
decreases to 17% of users at five years.   
A study in South Africa found that some of the discontinuers were “taking a break” 
from injectables.[28]  The majority of these women stated bleeding problems as the reason 
for the break and reported they intended to return for another injection when their normal 
menstrual cycle returned. In a study in the Philippines, DMPA users also reported waiting 
until their menstrual cycle returned to receive their next injection.[29] Clearly, this improper 
use of DMPA may lead to unintended pregnancies. 
Several studies of hormonal methods have found an association between menstrual 
side effects and discontinuation.[30, 31]  A study of injectables in Kenya found that 
menstrual changes were the main reasons for discontinuation.[32]  Using menstrual diaries, 
Tolley et al. found in Egypt that increases in duration of bleeding predicted discontinuation 
even when women did not perceive their menstrual length had changed.[33] 
Weight changes 
DMPA users may experience weight gain or feel bloated.[16] The gain in weight is 
probably due to increased appetite (an effect caused by progestin) and not fluid retention.  
The DMPA inserts says users may gain 5.4 pounds (average) during the first year, 8.1 
pounds after 2 years, and 13.8 pounds after four years of use. 
Mood changes, depression 
While overall depression levels among DMPA users do not increase, individual 
women may respond to the medication with increases in depression.[16] Given the longevity 
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of DMPA and the inability to discontinue immediately, service providers are cautioned about 
the use of DMPA with women who have a history of severe postpartum depression. 
Reduced libido 
A qualitative study of DMPA users in Quirino Province of the Philippines found that 
women experienced decreased interest in sex and vaginal dryness during intercourse, 
which may lead to marital problems.[29]  These side effects were also mentioned among 
injectable and pill users in a qualitative study in Kenya.[34]  The loss of sexual desire due to 
hormonal contraceptive use may cause some husbands to think their wives are having 
sexual relations with other men.[34] 
Recent studies among South African progestin-only injectable users highlight an 
opposite effect of this method on vaginal secretions—vaginal wetness.[35]  While not 
described in the published medical literature, this side effect was the second most common 
side effect mentioned (after amenorrhea) by injectable users in a community-based cross-
sectional household survey in a rural district of KwaZulu-Natal in South Africa.[36]  In 
several parts of central and southern Africa “dry sex” is practiced and the side effect of 
vaginal wetness is perceived as undesirable.[37-40]  In the study in KwaZulu-Natal, for 
example, almost 18% of injectable users reported this is what they liked least about the 
method.[36]  
Clinical health concerns of DMPA injectables 
The previous section described short term side effects that, while certainly important 
for discontinuation and method satisfaction, generally do not cause serious morbidity or 
mortality.  This section reviews the latest research on health concerns of injectables which 
may cause fear among users and thus influence discontinuation of these methods. 
Cardiovascular disease 
Progestin-only injectables do not contain estrogen and therefore do not appear to 
cause any of the cardiovascular complications associated with pill use.[16] However, some 
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studies have found decreases in high density lipoprotein (HDL) and increases in total and 
low density lipoprotein (LDL) cholesterol levels associated with injectables. 
Sexually transmitted infections (STIs) 
Baeten and colleagues examined the relationship between hormonal contraception 
use and the risk of STIs in a prospective cohort of HIV negative sex workers in Mombasa, 
Kenya.[41] Compared to those using no contraception, DMPA users were at increased risk 
of chlamydia infection and decreased risk of bacteria vaginosis, trichomoniasis, and pelvic 
inflammatory disease after controlling for sexual behavior and demographic factors.  There 
were no associations detected between DMPA and gonorrhea, vaginal candidiasis, syphilis, 
and genital ulcer disease.  The authors credit the biological plausibility of these findings to 
animal studies which suggest a link between the progesterone hormone and growth of 
Chlamydia trachomatis genital infections.[41] 
Human immunodeficiency virus (HIV) 
Women with genital tract infections, including chlamydia, have increased 
susceptibility to HIV infection.[42]  DMPA does not provide protection against HIV and may 
be associated with chlamydia infection as described above; therefore, it is logical to 
investigate the relationship between use of these hormonal methods and HIV infection.   
Seven studies have investigated the relationship between DMPA and HIV and have yielded 
mixed findings.[43-50]  Two of the studies found an increased risk of HIV among DMPA 
users[44, 48] and five found no association.[43, 45, 46, 49, 50]  The studies which found an 
increased risk have focused on high risk populations such as sex workers, limiting 
generalizability to the general population.[51] Moreover, several studies have 
methodological shortcomings which undermine the findings.[49, 51, 52] 
A recent prospective study of a South African cohort of women aged 35-49 years 
found no association between HIV risk and DMPA or NET-EN use.[53]  However studies in 
Uganda and Zimbabwe suggest that age may have a modifying effect on the relationship 
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between hormonal contraceptive use and HIV acquisition.[49, 51]  While this study found no 
overall increase risk of HIV acquisition, it found an increased risk among women 18-24 
years for DMPA users, but a decreased risk of HIV acquisition for users 25-35 years. 
Cervical and breast cancers 
Cervical cancer is caused by certain types of the human papilloma virus (HPV).[54]  
Not all women with HPV develop cancer; therefore other factors must be influencing the 
progression to cancer in HPV infected women.  It has been hypothesized that hormonal 
contraceptive use, including progestin-only injectables, may increase the risk of cancer of 
the cervix.  However, a case-control study conducted in South Africa did not find a 
relationship between injectable use and risk of invasive cancer of the cervix.[55]  Similarly, 
no relation was found between DMPA use and increased risk of cervical cancer in a WHO 
Collaborative Study.[56] 
Interest in whether DMPA use increases the risk of breast cancer stems from animal 
studies which found that DMPA induces mammary tumors in dogs.[57]  Indeed, this was the 
reason for the delay in licensing the contraceptive in the United States.[58]  Three studies, 
including one case-control study in South Africa, did not find an association between DMPA 
use and the risk of breast cancer.[59-61]  A New Zealand study found an overall relative risk 
(RR) of breast cancer to be 1.0 for DMPA users (no association).[59] When subgroups were 
analyzed, however, a RR of 2.0 was found among users 25 to 34 years and the risk was the 
greatest among women who used DMPA for six or more years.  These finds suggest that 
DMPA may accelerate the presentation of breast cancer in young women. 
Bone density 
DMPA prevents ovulation and strongly inhibits estrogen production from ovaries.[62]  
Estrogen deficiency among DMPA users adversely affects bone mineral density.[62-64]  A 
decrease in bone density may increase the risk for osteoporosis later in life.[64]  The effects 
may be especially detrimental before achievement of peak bone mass, as is the case for 
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adolescent DMPA users.[63]  A population-based prospective cohort study, however, found 
substantial post-discontinuation recovery of bone.[64]  This finding indicates that the effects 
on bone density may be reversible after cessation of DMPA.  The WHO medical eligibility 
criteria currently state that the advantages of DMPA generally outweigh the theoretical or 
proven risk of bone density loss for women under age 18.[65] 
Fears about DMPA injectables 
Women may also discontinue injectables if they believe continued use of the method 
will lead to health problems.  While not founded in medical literature, such fears may be just 
as important as those discussed above for those interested in decreasing contraceptive 
discontinuation.  Some documented fears about injectables, many of which stem from 
menstrual changes associated with hormonal methods, include the fear of infertility, an 
accumulation of blood in the body, loss of balance, and fear of delivering deformed children. 
Infertility 
A qualitative study of young men and women in Mali highlights the important social 
consequences of menstrual disruption that hormonal contraceptive users may face.  
Amenorrhea or prolonged bleeding induces fears of sterility among young women, a dire 
consequence in a culture which places a woman’s value on her ability to produce 
children.[66]   
Injectables do not cause infertility, but the longevity of DMPA in women’s bodies may 
delay the return of fertility up to a year, which may cause some women to fear infertility.[16, 
27]  While the median time to conception following the expiration of the last dose is six 
months, studies have shown that it could take up to 9-10 months for ovulation to return.[16] 
A cross-sectional clinic-based survey in two regions of the Western Cape of South Africa 
assessed women’s preferences for DMPA compared to the other common injectable, NET-
EN.[67]  Among women who preferred NET-EN over DMPA the most common reason for 
their preference was that NET-EN was thought to better preserve future fertility. 
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A qualitative study of sexually active and virgin US adolescents suggests further 
global evidence surrounding fears of menstrual disruptions.  This study, which asked 
minority women aged 12-18 years what they have “heard” about hormonal methods, found 
concerns about menstrual side effects emerge as a frequent theme.[68] Specifically, the 
authors identified the following four themes: (1) menstruation is natural and should not be 
altered; (2) menstruation is necessary for cleansing the body; (3) intermenstrual bleeding 
and amenorrhea may indicate the method is not working; and (4) menstrual irregularity may 
affect fertility and physical health.  The population in this US study obviously differs 
substantially from Kenyan women, however, without a comparable study in Kenya to 
compare, these themes provide insight into some of the possible concerns women may 
have regarding hormonal methods. 
Accumulation of blood in the body 
A qualitative study of the contraceptive practices and understanding of Filipino 
women found they believe that menstruation keeps women healthy and would prefer an 
increase in menstruation over a decrease or amenorrhea.[29]  In particular, the women view 
menstrual blood as dirty and therefore believe blood needs to come out for a woman to be 
clean.  According to the women, the lack of menstruation associated with hormonal 
contraceptive use results in an accumulation of dirty blood in the body which can lead to 
side effects such as headache, dizziness, blurry vision, hotheadedness, and even bleeding 
from the nose and mouth. 
Loss of balance 
The women in the Filipino study described above feel the experience of side effects 
during contraceptive use is an indication that the contraceptive method is not suitable for 
their body.[29]  For most of the women in this study, weight loss during contraceptive use is 
a sign that the method is not suitable for that particular woman.  A study among women in 
the Nyanza Province, Kenya also found that women believe side effects are a signal to the 
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woman that (p 301) “a particular contraceptive does not ‘rhyme’ with her body.”[34] This 
belief has important implications for discontinuation of hormonal methods since many 
methods, including injectables, have minor side effects. 
Deformed children 
In the qualitative study in Kenya discussed above, women feared that pills may 
cause birth defects, such as children born with multiple heads, lameness, missing or extra 
eyes, or no skin.[34]  Severe side effects are believed to be the result of improper use of 
pills such as missing pills or receiving the pills from an untrained provider.  Unusual side 
effects like these, however, were only discussed in about one-third of the conversations in 
the in-depth interviews conducted by the researchers during this study.  No similar data 
could be located about injectable use, but findings from this pill study may provide insight 
into women's fears about other hormonal methods like injectables. 
Multiple side effects 
While the side effects have been presented one-by-one above, injectable users may 
experience multiple side effects sequentially or simultaneously.  Multiple side effects 
increase the likelihood of discontinuation.[30]  A study of Canadian DMPA users found that 
menstrual changes combined with depression and/or weight gain are primary reasons for 
discontinuation after the first injection.[69] 
Interventions aimed at increasing continuation rates are sparse 
Given its prevalence and direct impact on the rate of unintended pregnancies, 
discontinuation of hormonal methods should be a top priority of family planning programs 
worldwide.  Unfortunately, interventions aimed at reducing discontinuation are sparse. 
Recently, an evaluation was conducted in Nicaragua of the Decision-Making Tool for Family 
Planning Clients and Providers developed by the WHO’s Department of Reproductive 
Health and Research and the Johns Hopkins University Center for Communication 
Program.[27, 70]  The evaluation found no differences in continuation rates among clients 
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attending experimental clinics who used this counseling tool compared to clients from 
control clinics, despite the experimental group reporting significantly better counseling 
experiences than the control.[70]   
Several other studies have demonstrated that intensive counseling about side effects 
increases continuation rates of injectables.[71-73]  However, adequate counseling does not 
appear common in Kenya.[14]  Indeed, less than half of modern contraceptive users 
reported that they were informed of other methods available or about side effects of the 
method they were provided.  No other types of interventions aimed at increasing 
continuation rates could be located in the peer review literature. 
In a Cochrane systematic review, only one out of six randomized control trials 
(RCTs) of enhanced counseling studied showed improved continuation of hormonal 
methods.[10]  The RCTs were conducted in Slovenia (former Yugoslavia), Mexico and four 
US cities, limiting the generalizability of this study to the Kenyan context.  The authors of this 
review recommended that interventions to improve continuation of hormonal methods focus 
on pre-emptive intensive counseling about side effects coupled with multiple contacts.  
Communication campaigns—which deliver messages repetitively—may be a viable solution 
to improve continuation. 
A communication campaign is a promising strategy for delivering information about side 
effects, with the goal of increasing continuation rates 
Communication campaigns have been associated with increased adoption of contraception 
around the world.[74-78] A study conducted in Tanzania found a positive association 
between recall of a family planning message from a national mass media campaign that 
included family planning radio dramas, and use of a modern contraceptive method.[79]  The 
authors consider radio as one of the best methods for disseminating family planning 
messages in this setting.  An analysis of DHS data from six African countries found that 
exposure to media in general was associated with higher contraceptive use in all countries 
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examined.[74]  In three of the countries—Kenya, Madagascar and Ghana—exposure to 
family planning messages on the radio was associated with higher contraceptive use after 
controlling for a host of socio-demographic factors and general media exposure. 
In addition to mass media, communication campaigns can employ lay health 
advisors to disseminate family planning information or reinforce mass media messages in a 
community.  A longitudinal study in Bangladesh found a five times greater rate of increase in 
modern contraceptive use among women who participated in a series of group discussions 
in their community organized by trained family planning field workers compared to women 
who were visited by a family planning field worker in their home.[80] 
As demonstrated above, research to-date remains inconclusive with regards to the 
effectiveness of interventions which aim to improve quality of services and counseling on 
continuation rates.  Communication campaigns using mass media have not been fully 
examined for their potential to increase continuation of hormonal methods. 
In Kenya exposure to family planning messages in the media is high.[14]  Seventy 
five percent of women heard or saw a message about condoms on the radio, television or in 
a newspaper/magazine in the past few months.  Radio is the most common source (73%), 
followed by television (37%) and newspaper/magazine (35%).  Moreover, the majority of 
women (68%) surveyed found it acceptable to air condom messages in the media. 
Given its ability to influence contraceptive adoption and the potential reach to millions of 
Kenyan women, a communication campaign may serve as a promising method for delivering 
information about and management of side effects.  This hypothesis will be assessed in the 
intervention study (expected 2010).  The purpose of this dissertation is to provide the crucial 
foundation for interpretation of the findings of the intervention study. 
The previous sections presented the public health implications of contraceptive 
discontinuation, the contraceptive use and discontinuation context in Kenya, the 
determinants of premature discontinuation of contraceptive injectables, and intervention 
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strategies to increase continuation.  In the next section the theoretical model for this 
dissertation is discussed. 
Theoretical Model 
Expansion of the Bruce-Jain framework with components from the Theory of Reasoned 
Action provides a model for predicting continuation 
In 1989 Jain proposed an analytical model linking quality of family planning services 
to fertility through contraceptive prevalence, acceptance and continuation of contraceptive 
methods.[8]  Jain's model, illustrated to the step of contraceptive prevalence, is depicted in 
Figure 1.  The definition of quality of services in this model is based on the concept of quality 
of care proposed by Bruce in 1988. [81] 
Under the heading of quality of services, Jain hypothesized the following to be 
predictors of continuation: choice of contraceptive methods, information given to users, 
provider competence, client/provider relations, re-contact and follow-up mechanisms, and 
appropriate constellation of services.  Choice refers to both the number of methods 
consistently available and variability among the different methods offered.  Jain suggests 
users be informed about (1) contraindications, risk and benefits of the method, (2) how to 
use the method, potential side effects, and how to manage side effects, and (3) what users 
can expect from providers in terms of support, supply and referrals.  Provider competence is 
the skill level and experience of the service provider.  Client/provider relations describe the 
quality of the contact and communication between clients or potential clients and the 
provider.  Follow-up mechanisms are the efforts employed to promote the continued use of 
family planning methods.  Appropriate constellation of services entails positioning services 
so they are acceptable and convenient to couples. 
Quality of services are primarily considered supply factors in this model.  Demand 
factors, including fertility motivations, influence continuation as well.  Jain considers the 
couples' desire or motivation to regulate their fertility to be the most important factor 
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affecting demand for contraception. These factors are encompassed in the box labeled 
“Demand and other factors” in Jain’s model. 
 
This dissertation does not test all of Jain’s model, but uses elements of the model as 
a foundation and then expands the model using constructs from the Theory of Reasoned 
Action (TRA). TRA was developed to understand the relationship between attitudes and 
behaviors.[82-84]  TRA is founded on the premise that the most important predictor of 
behavior is an individual’s behavioral intention.  Behavioral intention is influenced by an 
individual’s attitude toward performing the behavior and their subjective norm associated 
with the behavior.   
Attitudes toward performing the behavior are dependent upon beliefs about 
outcomes of performing the behavior weighted by the individual’s evaluation (or value 
placed) of those outcomes.  In the context of this dissertation, potential users' salient beliefs 
about continuing to use a contraceptive method need to be determined and addressed for 
behavior change to occur.  Specifically, beliefs that inhibit the desired behavior should be 
countered and those that encourage the behavior should be supported.   
Quality of Services 
• Choice 
• Information to users 
• Provider competence 
• Client/Provider relations 
• Follow-up 
• Appropriate constellation 
Acceptance 
Continuation 
Contraceptive 
prevalence 
Known effects 
Hypothesized effects 
Demand and other factors  
Figure 1.1:  Model from AK Jain (1989) 
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Subjective norm is influenced by perceived attitude of important referents (i.e., family 
members, friends, health care provider) towards the behavior the individual is considering, 
weighted by the individual’s motivation to comply with those referents (or the value they 
place on the referents’ opinion). With regards to this dissertation, the salient referents are 
important groups of people who influence the contraceptive behavior of the users.   
The TRA components of behavioral and normative beliefs can be used to expand 
Jain's framework to include perceived side effects and health concerns held by 
contraceptive users and their salient reference groups.  While Jain acknowledges that users 
need to be informed about potential side effects of methods, the provision of such 
information during a brief counseling session with a medical professional may not change 
users' beliefs, which are often deeply entrenched in and reinforced by cultural norms.  
Moreover, Jain's concept of "information to users" only includes those side effects which 
were demonstrated in clinical studies of specific contraceptive methods and not the actual 
beliefs or fears users may hold about use of contraceptives.  This is an important distinction 
because, as previous research demonstrates, the side effects reported in medical 
publications may be different from the concerns of potential users.  According to TRA, failure 
to address users' perceived side effects and health concerns, even if these concerns would 
be considered myths by medical professionals, will thwart behavior change.   
Jain's model ignores the influence of salient referents or important groups of people 
who influence the contraceptive behavior of the users. According to TRA, salient referents 
and their beliefs about potential users continuing to use a contraceptive method need to be 
identified and incorporated into interventions aimed at changing behavior.  Evidence from a 
previous qualitative study in four developing countries suggests that interventions focusing 
on contraception should involve husbands, friends, and family members of the users.[85]  
Women reported that these referents influence their decision to use, continue using and 
remove a subdermal contraceptive implant. In two of the countries studied, Egypt and the 
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Dominican Republic, mothers and mothers-in-law were especially influential in decisions 
affecting fertility and expressed the most resistance towards the method and the most worry 
about side effects.  This dissertation includes the perspectives of salient referents that were 
omitted in Jain’s model. 
Significance 
The research in this dissertation lays the ground work for the evaluation of the 
intervention study (expected 2010).  As discussed above, communication campaigns may 
be a viable solution to increase continuation of hormonal methods; however their potential 
has not been fully examined.  The intervention study is the first of its kind to utilize a 
communication campaign to increase contraceptive continuation rates. If proven effective, 
this intervention strategy may serve as a model for other African countries experiencing high 
discontinuation rates and thereby have significant public health impact.   
This dissertation is structured as two related papers followed by overall conclusions.  
The methods are described in detail in each paper.  The first paper addresses the first aim, 
to identify reasons why women in Nyando District Kenya discontinue using contraceptive 
injectables from the perspectives of current users and their salient referents.  Findings from 
this qualitative study are used to suggest points of intervention for future efforts at increasing 
continuation of family planning methods among injectable users in Nyando District.  
Additionally, the achievement of this aim will provide contextual information for interpretation 
of the evaluation findings from the intervention study. 
The second paper addresses the second and third aims using prospective 
longitudinal data measuring pre-intervention continuation rates from two districts in Kenya.  
The goals of this paper are to describe the factors which predict the occurrence and timing 
of contraceptive discontinuation among first-time contraceptive injectable users still in need 
of family planning in the two study districts before implementation of the communication 
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campaign, and to determine if the rates and predictors of discontinuation differ between the 
districts before implementing the communication campaign. 
Building on the literature, the factors hypothesized in the second aim to predict 
discontinuation in the two study districts are those found in previous studies of contraceptive 
discontinuation in other locations around the world.  This dissertation also extends existing 
literature by measuring several factors which have not been explored in previous studies of 
contraceptive continuation, but that health behavior theories such as the Health Belief 
Model, Theory of Planned Behavior, and Social Cognitive Theory suggest may be important 
determinants of continuation behavior. These theories have been shown to predict 
numerous other health behaviors and therefore should be explored for their potential effect 
on contraceptive continuation behavior.  [86]  
It is important to determine if similar factors influence discontinuation in the study 
districts because this finding would provide support for universal (versus local) reasons for 
discontinuation.  It is important to note that finding that a particular factor is “significant” at 
one site but not at the other does not imply that the association of that factor with the 
outcome differs between the two sites. However, if similar reasons for contraceptive 
discontinuation are found in diverse samples, public health practitioners could develop and 
recommend universal or template intervention(s) for increasing continuation.  However, if a 
set of different predictors is found in diverse samples then a more tailored approach is 
indicated.   
In addition, the findings from the second aim are used to suggest characteristics that 
predict discontinuation of family planning methods while still in need among women in this 
population.  Given limited funds for family planning, public health practitioners could use this 
information to target women most at-risk for premature discontinuation with efforts to 
increase contraceptive continuation and reduce unintended pregnancies. 
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The results of the third aim are vital to the interpretation, and ultimately utilization, of 
the findings from the evaluation of the intervention study.  The third aim, to determine if the 
rates and predictors of discontinuation differ between the study districts before 
implementation of the communication campaign, is necessary because the evaluation relies 
on quasi-experimental methods. 
Communication campaigns are designed to reach the masses and therefore, the 
products developed for campaigns (radio spots, posters, etc) are widely distributed.  Even if 
a particular media product is targeted to one particular group it is difficult to prevent people 
outside this target group from accessing the products.  The very nature of a campaign, 
therefore, makes it impractical to conduct a randomized experiment to evaluate the 
effectiveness of a campaign.  Quasi-experimental designs test descriptive causal 
hypotheses about manipulable causes without random assignment of subject to treatment 
and control conditions.[87]  Instead, assignment to treatment conditions occurs by self-
selection, which may result in systematic differences between the treatment and control 
groups other than the presence of the treatment.  Self-selection may lead to selection bias, 
which is a threat to the internal validity of the study.  Since quasi-experimental designs 
create less compelling support for counterfactual inferences, alternative explanations for the 
study findings must be ruled out to get a more valid estimate of the treatment effect. 
For the intervention study the lack of randomization means that we cannot be sure 
that the new contraceptive injectable users in the treatment and comparison districts do not 
differ in systematic ways other than being exposed to the intervention (the communication 
campaign).  While the two study districts in the study have been carefully selected to be as 
equivalent as possible on the factors thought to influence the outcome (i.e., urbanization, 
sexual practices, and fertility desires), in the absence of randomly assigning new injectable 
users into treatment (receive the campaign) and control (do not receive the campaign) 
conditions, selection bias may be an alternative explanation for the evaluation findings.  
 23
Moreover, even a rough estimate of the degree of equivalence between the pre-intervention 
(baseline) discontinuation rates of the two districts is unavailable because discontinuation 
rates are lacking for many smaller geographic units, such as the two districts in this study.  
Given these deficiencies, the evaluation for the intervention study uses an untreated 
comparison group design with independent pretest and posttest samples.  Selection bias is 
assumed to be present because the two groups (districts) are nonequivalent.  The pre-
intervention study allows for the measurement and comparison of baseline discontinuation 
rates (the outcome) between the two districts.[87]  The assumption is the smaller the 
difference in pre-intervention discontinuation rates among the two districts is, the lower the 
likelihood of initial selection bias and the more confidence we can place in the evaluation 
findings. 
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CHAPTER 2. Reasons for discontinuation of contraceptive injectables: A qualitative 
assessment of contraceptive utilization among current users and their salient 
references in Nyando District, Kenya 
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Abstract 
Discontinuation of contraception is a major problem in Kenya. A quarter of women 
abandon their contraceptives within 12 months of beginning use, despite still being in need.  
Focus group discussion (FGDs) were conducted in Nyando District, in western Kenya, to 
identify target groups and appropriate messages for a communication campaign to increase 
contraceptive continuation.   
Fourteen FGDs were conducted among current contraceptive injectable users and  
salient references,  people who influence women’s use and discontinuation of contraception.  
Four were with current users and two with each of  five salient reference groups:  husbands, 
mothers-in-law, community leaders, service providers and long-term contraceptive injectable 
users.  The purpose of the FGDs was to understand why women discontinue using 
contraceptives (with a focus on injectables). Thematic analysis was performed using NVivo 
8 software. 
Discontinuation of contraceptives in Nyando District occurs for logistical, social and 
medical reasons.  Women do not always have control over continued use of contraception. 
Common reasons for discontinuation include side effects, husbands’ opposition, provider 
and/or clinic restrictions, misconceptions about injectables, stock outs, and lack of cash to 
purchase contraceptives or pay for family planning (FP) services. Current users and 
reference groups have low knowledge of side effects of contraceptives, especially 
injectables, and lack of adequate knowledge about injectables was a key factor in 
discontinuation.   
This research expands the literature by examining social influences on 
discontinuation by incorporating the perspectives of salient reference groups.  The results 
suggest points of intervention for increasing continuation in this community and similar 
resource-poor settings.   
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Introduction 
In the late 1970s, Kenya had the highest fertility rate in the world.[1]  Through public 
health efforts, the country has since experienced one of the most dramatic fertility declines.  
The decrease in the fertility rate has been attributed to the increase in contraceptive 
prevalence.[1] According to the 2003 Kenya Demographic and Health Survey (KDHS), 33% 
of married women were using a modern method, but 25% of all contraception users 
discontinued within 12 months of beginning use, despite still being in need of family planning 
(not due to desire for pregancy or reduced risk to pregnancy). [2] One-fifth of the 
pregnancies in 2003 and the births in the five years preceding the 2003 KDHS were 
reported as unwanted and a quarter were reported as mistimed.  Contraceptive 
discontinuation in Kenya has increased since the 1998 KDHS and the increase has been 
attributed to the relatively high discontinuation rates for pills and injectables. [2,3] The 
predominant method used in 2003 was injectables (14% of currently married women), 
followed by the pill (8%).  Despite its popularity, 21% of injectable users discontinue use of 
the method within 12 months of starting, despite still having family planning (FP) needs.[2] 
FP service-related factors, including quality of care, have been thought to be 
associated with contraceptive discontinuation.[4]  However, studies of quality of care have 
not been able to show large effects on discontinuation rates.[5-8]  Consistent determinants 
of discontinuation include:  type of method used, side effects, age (younger women are 
more likely to discontinue than older women), fewer number of living children, fertility 
intentions (women wanting to increase space between their children are more likely to 
discontinue compared with women who have completed childbearing), and a change in 
marital status.[9]  Discontinuation appears to be less consistently associated with the 
number of methods available [5], socio-economic factors including education [9-11], urban-
rural residence [11], husband’s disapproval [12], cost or lack of access to the method [5,10]. 
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In Kenya, side effects are the most common reason for discontinuation,  
predominantly due to side effects associated with pills and injectables.[2] Among the 
discontinuations reported in the five years before the KDHS, the percentages that were 
attributed to side effects increased from 20% in 1998 to 25% in 2003.  In 2003, 13% of 
currently married women not currently using a method reported that they do not intend to 
use a method in the future because of fear of side effects.  The proportion increases to 20% 
for women under 30 years of age. 
The term "side effects" encompasses the following two categories:  clinical side 
effects and health concerns, and health-related fears.  Clinical side effects and health 
concerns are those which have been evaluated through research studies and are found in 
published medical literature.  The most common reason for discontinuation of hormonal 
methods is disruption of the menstrual cycle.[13] Menstrual irregularity (increased number of 
days of light bleeding or amenorrhea) is very common among injectable users.[14] Other 
clinical side effects and health concerns associated with injectable use include:  weight gain, 
mood changes, reduced libido, headaches, dizziness, abdominal bloating/discomfort, 
nausea and reduced bone density. [15-20] 
The second category includes health concerns that women fear or worry about, yet 
which have no basis in the medical literature.  Some call these fears myths; however, as a 
cause of discontinuation, these fears are as important as documented clinical side effects. 
Women may stop using injectables if they believe continued use of the method will lead to 
health problems.  Some documented fears about injectables, many of which stem from 
menstrual changes associated with hormonal methods, include the fear of infertility, an 
accumulation of blood in the body, loss of balance, and fear of delivering deformed children. 
[14,17, 21, 22] 
While previous research has primarily focused on user and method-
related characteristics associated with discontinuation, little attention has been paid to the 
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influence of other people on discontinuation.  This is a significant omission because women 
do not make family planning decisions in isolation, but rather their contraceptive behavior is 
influenced by their social enviroment, including cultural norms.  In an effort to identify target 
groups and appropriate messages for a communication campaign to increase contraceptive 
continuation among contraceptive injectable users, focus group discussions (FGDs) were 
conducted in Nyando District, Kenya in 2007.  This research expands our understanding of 
discontinuation by examining social influences on discontinuation by incorporating the 
perspectives of salient reference groups.  The results of this analysis are used to suggest 
points of intervention for increasing continuation of FP in this community and similar 
resource-poor settings.   
Methods 
Fourteen FGDs were conducted among current contraceptive injectable users and 
their salient references, which are groups of people who influence women’s use and 
discontinuation of contraception.  First, four FGDs were conducted with current 
contraceptive injectable users recruited from Ministry of Health Family Planning clinics in 
Nyando District, Kenya to determine why women discontinue using contraceptives (with a 
focus on injectables) and identify their salient references.  FGD data from current users were 
analyzed and five salient reference groups identified for a second round of  FGDs. Then two 
FGDs were conducted with each of the groups:  husbands, mothers-in-law, community 
leaders, service providers and long-term contraceptive injectable users.  Table 2.1 shows 
the number of participants in each FGD. 
A local research company experienced in conducting social science research in the 
study area recruited participants and conducted the FGDs.  The FGDs were led by 
experienced, trained interviewers, fluent in the local language, Dholuo.  Due to the 
sensitivity of the study topic,  interviewers were the same gender and roughly the same age 
as focus group participants.  We used a semi-structured open-ended FGD guide.  The same 
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questions were asked in the same order of all participants and responses were inductively 
probed.  Discussions were tape recorded and transcribed verbatim and then translated to 
English.  The FGDs consisted of 8-12 participants and were homogenous with respect to 
gender and respondent type (i.e., current user, service provider, community leader).  The 
discussions averaged 1.5 hours. 
A detailed codebook was developed by both authors where themes (reasons for 
discontinuation) were identified and defined.  Several codes were predetermined based on 
FP literature, but the majority of codes were created inductively, and therefore, generated 
from  reading the transcripts.[23,24]  This inductive thematic approach allows themes to 
emerge from the data.[25] 
Transcripts were coded by the first author using QSR’s NVivo 8 software.[26]  The 
cross tabulation reporting function (“matrix coding”) was used to identify patterns in themes 
by respondent type. Based on these reports, both authors examined the evidence that 
supports each theme quantitatively (i.e., code application frequencies by type of participant 
generating the data) and qualitatively (i.e., context of code).  To capitalize on the FGD 
enviroment, we looked for participant interactions (i.e., encouragement, disagreement) with 
groups.[27] The results section features quotations from FGD participants. 
Results 
A total of 65 themes were identified, of which 21 were predetermined based on the 
FP literature.  We placed these themes into three higher- level conceptual constructs with 
regard to why women discontinue using contraceptive injectables in Nyando District:  
logistical, social, and medical reasons for discontinuation.  Logistical reasons include clinic 
restrictions and service providers’ lack of knowledge about injectables, which lead to 
premature discontinuation, difficulties getting to the clinic for injections, stock outs, and lack 
of cash to pay for clinic visits and/or injectables.  Social reasons include salient reference 
group (i.e., husbands, mother-in-laws) oppositition to contraceptive use, and religious and 
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cultural beliefs that prohibit or thwart contraceptive use.  Medical reasons encompassed 
clinical side effects and health concerns, and health-related fears about contraceptive 
injectables.  Participants used various names to describe contraceptive injectables 
including:  the jab, injectables, Depo, and Depo Provera.  Some just referred to the method 
as family planning.  Table 2.2 provides a summary of the 56 codes which were expressed in 
at least two FGDs. 
 
Logistical reasons 
 Logistical reasons were mostly given by service providers, and current and long-term 
contraceptive injectable users.  Clinic restrictions, lack of knowledge about injectables, stock 
outs, and lack of cash were the most common themes.  Participants in both FGDs with 
husbands mentioned lack of cash and stock outs as a reasons for discontinuation.  Common 
clinic restrictions include service providers only allowing women who already had multiple 
children to receive injections and requiring husbands’ permission to receive an injection.  
One current injectable user explains who can use injectables in her community, 
 It depends on the number of children that you have. Maybe you sat down with your 
husband and you have agreed that you want to plan your family plan, so you can 
agree and go to the doctor. Doctors sometimes don’t agree. Maybe if you have one 
child and you want to stop giving birth, he [the doctor] can’t allow you because he 
knows that you will need another child. So in a house you can have three children. 
This one he [the doctor] can allow you to use injectable, especially if you have 
discussed with your husband because he will first ask you if you have discussed the 
issue with your husband. [CIU, FGD 1] 
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Some of the service providers agreed with a parity restriction, while others did not.  When 
asked what types of women can receive FP injections in the clinics, three service providers 
[FGD 1] responded: 
 R2:  All women of child bearing age but there seems to be contraindication for 
women who have not given birth because if you open the [injectables] pack, it says 
that it should be used with women who have at least one child because it delays 
fertility. So they have written it clearly. 
 R6:  I would say the method would depend on the person who is to use it. Also as 
my colleagues have said, about the age and the parity of the user. 
 R4:  I want to react to what [R2] said. To me it would appear misleading if we say 
women who have not given birth are contraindicated to injectables. What I say is that 
we give them information. They are the decision makers. Having let them know that it 
will delay the ovulation and they still want to use the method, you should just allow 
them to use. 
 
A similar discussion emerged in the second FGD with service providers.  When asked the 
same question about who receives injectables, a service provider responded, “Any mother 
who has started seeing her menses.”  Indeed, “mothers” was the most common answer in 
all FGDs to the question about who uses contraceptive injectables in this community 
indicating that this method is primarily used by women who already have children. 
As aluded to in the above quotation, another common clinic restriction is that women 
have to be menstruating to receive the initial injection.  Often, if women are not menstruating 
on the day they visit the clinic, they are sent home and asked to come back when they are 
mentruating.  In some clinics, women are also required to present their FP card to receive 
their next injection.  A current injectable user [FGD 3] explains how this restriction can 
prevent contraceptive continuation in her community, “Sometimes if the man [husband] sees 
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that the child has grown and the neighbor has a baby, he can even take your [family 
planning] card and hide it and that’s your end with family planning.” 
Service providers identified several side effects of injectables which cause them to 
not re-inject clients.  Many of these side effects are not supported by medical research, 
including hypertension, low body weight, and short menstrual cycles.  When asked why 
women stop using injectables, a service provider [FGD 1] responded: 
 Due to side effects like hypertension, they come to the facility and after sometime, 
the [blood] pressure increases. Maybe she didn’t have [high] blood pressure but after 
using it [injectables], she develops [it]. So you can advise her to stop. 
 
Stock outs of injectables was a problem mentioned in over half of the FGDs.  When a clinic 
runs out of injectables, they ask clients to buy the injectables at a pharamacy and return to 
the clinic for injection.  In addition to the extra financial and time costs associated with 
traveling to the pharmacy, this solution poses an insurmountable financial constraint to 
many clients since the pharamacies charge a much higher price than FP clinics, which often 
provide methods free or at a nominal charge.  According to the service providers in the 
FGDs, many clients who leave the clinic without receiving their injection do not return.  One 
long-term user [FGD 2] describes how injectable users can become discouraged when the 
method is out of stock at the clinics and not affordable at pharmacies and private hospitals: 
 It can reach a time when the injectables are not there [in the family planning clinics]. 
Even if we go to the places where we get them from, you can be discouraged until 
you stop because you go and you find that they are not there. There are some 
people who offer the same service but their price is high and sometimes you don’t 
have the money. 
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Another  long-term user [FGD 1] describes community health workers (CHWs) as a 
convenient source of injectables in her community when the clinic runs out of stock: 
 The hospital these days has no injectables for family planning, so you are sent to the 
clinic. Then you buy the drug. Then you can be injected because even if you go to 
the sub district or health centre, it’s expensive. But the CHW will only charge you ten 
shillings [approximately 0.12 USD]. And even the distance to Pap Onditi [clinic] is too 
much and when you reach, there you find a very long line. But the CHWs are just 
around so you can go back and perform your duties. 
 
Some of the service providers [FGD 1] suggest that the change in focus from FP to 
HIV/AIDS may be to blame for the stock outs as explained below. 
 … instead of concentrating on sustainability of supply of the same contraceptives, 
the idea [focus] is now based on HIV control and management. That now leads to 
the shortage of contraceptives and mothers stop using them because it is very 
expensive.  Depo-Provera is about 80-90 shillings [approximately 1 USD] in some of 
the chemists which is of course if somebody is not having the money cannot 
purchase and in the end conceives. 
 
Social  reasons 
Social reasons were mostly given by community leaders, husbands and current and 
long-term contraceptive injectable users.  Husbands’ opposition to contraceptive use was 
mentioned in all 14 FGDs.  Specific reasons for husband opposition included (in decreasing 
frequency):  decreased libido on the part of women (mentioned in all 14 FGDs), wants more 
children, preference for male children, changes in bleeding, and discovery of covert use.  
Participants explained that decreased libido may result in two situations.  First, women are 
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suspected of taking on a new sexual partner, or second, husbands may take a new sexual 
partner or second wife.  One husband [FGD 1] illustrates: 
 With me, the weakness that I see [in injectables] is that one for the bedroom. It 
removes appetite [libido] from women. They are not in the mood for sex. They are 
always tired.  I also see that it can destroy one’s marriage because if men are 
[sexually] active, men say that there is weakness for the garden and that one for bed. 
If the man is [sexually] active and the woman is not, it can lead the man to 
extramarital affairs. It can also make a man to marry another wife. 
Covert use (women using contraception without their husband’s knowledge) was 
described in all FGDs. However, in 11 FGDs participants also talked about both partners 
making contraceptive decisions together.  Mother-in-law opposition was mentioned in five 
FGDs. 
Religious opposition was mentioned in roughly half of the FGDs.  Participants 
specifically cite the Catholic church as being opposed to contraceptive use.  Participants in 
both FGDs with husbands and one with long-term users stated concern about FP reducing 
the population of the community.  A long-term injectable user [FGD 1] explains,  
 There was a member of parliament who was complaining that Luos [the name of the 
predominate tribe residing in Nyando District] are practicing family planning and that 
is why the population of Luos has gone down while the Kalenjins [another tribe] are 
giving birth and don’t even want to hear about family planning. So we should reflect 
back and go to our tradition. Before it us who were many and now we are few. So we 
should stop family planning and conceive and raise our population. 
 A belief that emerged in half of the FGDs and was distributed across all respondent 
types except mothers-in-law, was that contraceptive injectable use is associated with 
prositution.    When asked what category or type of women use injectables, community 
leaders [FGD 1] responded: 
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 R5: Most of them that we see, you find that they are women who had separated 
from their partners. Maybe she stays in Ahero [a nearby town] doing a business 
[prostitution]. She left her house. Most of those women use injectables. Young 
women who are widows at an early age also tend to use injectables. 
 R1: Back when the idea of family planning came, we were being taught that if you 
are below thirty years, you can’t be injected with injectable. But nowadays even 
school- going children from 18 years, 20 years and so on use injectable. That’s why 
you hear people say that young girls use injectables. Even those who have not 
known whether they will one day become pregnant use injectable. And also that has 
made prostitution increase.  
 R6: According to what was earlier said, I just want to say that they are business 
ladies [prostitutes]. 
 R8: You see family planning started early, nowadays even children of 18 years or 
16 years do it. But it’s not good. So it’s mostly from 18 to 45 [years]. Most of them 
are business ladies [prostitutes]. 
 R2: … another thing may be one was selling her ‘tomatoes’ [meaning selling her 
body or engaging in prostitution] and now she has got someone who has married 
her. She can decide to stop using injectables so that she can conceive because she 
has a husband. 
 
Medical  reasons 
Medical reasons for discontinuing injectables—both clinical side effects and health-
related fears of injectables—were common across all groups.  Beginning with clinical side 
effects, increased weight was mentioned in almost all of the FGDs.  This side effect was 
primarlily viewed negatively although participants in five FGDs expressed favorable opinions 
about increased weight.  Decreased bleeding or amennorhea was also mentioned in almost 
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all of the FGDs, although similar to increased weight, a few injectable users in four different 
FGDs expressed happiness with this side effect.  Below are perspectives from three current 
users: 
 There is something that I have observed about injection, I don’t know if it is me 
alone? [Asking question of the group] Sometimes I take long before I attend 
[menstruate], until I worry that I am pregnant. I don’t see any sign showing that I am 
pregnant. Do you know that has made me to worry so much! Because me “I am just 
seated that I am seated” [meaning that I am just there helpless], I do not see, 
sometimes it [period] comes a little and then disappears again. [Current user, FGD 2] 
 
 You know that when you are seeing blood then sex is back, or how is it? [seeks 
opinion of other participants] Secondly, if you are seeing blood then you still feel that 
you are in the league of younger women because those who don’t have menses we 
call them ‘bim’ [translates to ‘Chimpanzee’] in ‘Dholuo’, So if you are still seeing your 
menses, then that means that you are still young. [Long-term user, FGD 1] 
 
 I like it [amenorrhea] because the war with my husband during my periods is no 
more. [Current user, FGD 1] 
  
 Injectable users also talk about waiting for their menses to return before getting their 
next injection even if their current injection expires.  A long-term user [FGD 2] describes her 
re-injection patterns to the moderator: 
M: You were supposed to go back on 7th. Why didn’t you go back? 
R4: I wanted to see my periods because since I started using [injectables], I have 
not received them. 
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M: You’re waiting for periods? 
 R4: Yes 
 
Another long-term user [FGD 2] describes how her concerns about amenorrhea led her to 
discontinue using injectables while she waited for her period to return: 
R7: I had a break for one whole year without using it. 
M: Without using any [contraceptive method] and you did not conceive as well?  
R7: I did not use anything and after that whole year, I started using it again  
M: Why did you take a break? 
R7: I thought that since I was not seeing blood maybe they were getting collected 
somewhere in my body because since I began using the injectables, I had never 
seen blood.  
M: You thought the blood was being collected somewhere? 
R7: I thought they were being collected somewhere and when I asked the sister 
[nurse], she told me that there is nothing like that. But according to me, they were 
somewhere.  
M: Mmm. 
R7: Mmm. So I said that I want to have a break and see if the blood will come out 
after some time without the use of the injectables. Then use it again.  
 
Increased bleeding or spotting was mentioned in almost all the FGDs.  Husbands did 
not comment on bleeding increases or spotting; however both FGDs with husbands 
expressed dislike of amenorrhea.  One husband [FGD 1] recounts: 
 Injectables are good but its also not very good. For example a woman always goes 
for her periods monthly. When she is using injectables, then they can inject her for 
one that lasts for three months, I can’t talk about someone’s wife. For those three 
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months, a woman can miss her periods, after that she menstruates naturally… That 
makes them lack good health, even if she becomes fat, she is not very strong. 
Injectables make women unable to do other chores like going to the garden because 
they have no energy. They can only do office jobs. [Laughter] So you find that the 
woman cannot go to the garden. You know us --we go to the garden. You know the 
woman misses her periods but God put it that they should menstruate monthly. So 
that is where we don’t understand. It [injectables] makes them tired; it doesn’t want 
one to do heavy chores like going to the garden. 
 
As indicated  above, amenorrhea was associated with weakness and fatigue by 
some participants.  Some associated amenorrhea with reduced libido.  Backache was 
another common complaint.  Backaches were mentioned in 10 out the 14 FGDs.  In three 
FGDs, participants speculated that bleeding changes due to injectable use caused 
backaches among users.  One husband [FGD 2] commented: 
 They [injectable users] mostly complain about backache, which is as a result of lack 
of periods. Somebody stays [without periods] for quite a long time, even for three 
years consecutively without periods. This causes the back pain. 
 
As mentioned under the social reasons for discontinuation, lower libido was a 
common theme in all FGDs.  One mother-in-law [FGD 2] explained: 
 It [injectables] can sometimes bring problems in the house when it reduces your 
sexual libido, then when the husbands want their conjugal rights and you are not in a 
mood to respond. Now at that time, you know it is war. He will say that you have 
some people outside where you satisfy your sexual desires such that when he 
proposes to you, you do not accept him. 
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Interestingly, in two FGDs participants mentioned that reduced libidbo was a 
desirable side effect.  Two service providers [FGD 1] recount: 
R2:  Ok, I wouldn’t said it’s for the majority. But … for almost half of the women who use 
it, the libido is reduced. I can also say that there are women who come specifically 
for the injectables (e.g. the widows). … they don’t want to conceive and also they 
don’t want to get involved with other people, so if they use it their libido will be 
reduced. 
R7:  I agree with her, some women say that if they are using the injectables, their libido is 
reduced, especially widows. They liked Depo. 
 
Other common clinical side effects mentioned during the FGDs included:  abdominal 
discomfort, headaches, and delayed return to fertility.  Mood changes and nausea were 
mentioned in three FGDs.  Changes in vaginal lubrication were mentioned  in only two 
FGDs and was not a major theme.  Injection site pain was mentioned by only one participant 
and concern about loss of bone density was not mentioned at all. 
Health-related fears of contraceptive injectables were common in all FGDs.  The 
most common fears were infertility, delivering a deformed baby, and high blood pressure.   
Infertility was mentioned in 13 of the 14 FGDs.  Many of the participants recounted stories of 
people in their community who had used injectables in the past and as a result of this use, 
could no longer conceive.  One community leader [FGD 2] declares, “Another major problem 
is that the use of injectables can cause permanent sterility.”  A belief in this community is if a 
person uses injectables for five or more years, they will become infertile and this belief leads 
to discontinuation as one current user [FGD 1] describes, “Me, I discontinued using 
injectables because I could hear people say that if you use injectable for five years, you 
wouldn’t be able to give birth. Then I decided to discontinue and it is during that time that I 
conceived again.”  A mother-in-law [FGD 1] recounts: 
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 R2:  Some people stop using injectables depending with how she has used it so that 
she can get another baby. She may wait hoping to get another baby but she fails to 
conceive. This sometimes happen to people. 
 M:  That means that she stops [giving birth] permanently 
 R2:  Yes 
 
A mother-in-law in another FGD echos this belief, “On the use of injectable, they 
[current users] think that if they use injectables, then they won’t give birth again in their lives, 
so they develop some fear.”  Service providers [FGD 1] provide further explanation of this 
belief: 
R3:  They [family planning clients] have a belief that if you use Depo, you become 
infertile. So they fear using it.  
M:  Is it a belief or is it the truth? 
In chorus: It’s a belief. 
R2:  It can delay fertility but it can not make you infertile. 
R1:  You know what they always expect that if they stop using Depo, then they 
want to see their menses immediately. So if they fail to see their menses, 
they relate it to infertility 
 
In the second FGD with service providers, infertility was only mentioned once by one 
provider who stated that a side effect of injectables was “secondary infertility.”  This same 
provider also said that injectables can lead to hypertension and varicose veins.  None of the 
other service providers in that FGD spoke up to refute these claims.  High blood pressure 
was considered a side effect of injectables by service providers in both FGDs. 
Discussions about the fear of delivering a deformed baby as a result of using 
contraceptive injectables was common. However, the types of deformities mentioned varied 
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and included:  deformed, blind, one or no eyes; unproportionality, many or no legs; short or 
no limbs; small, big, malformed, multiple or no head; combined organs; facial deformity; 
paralysis;  missing fingers; mark on skin; two babies joined together; weakness; and 
delivering an animal (mongoose, cow, chimpanzee, monkey).  Some participants refute 
these claims explaining that deformities existed before injectables were invented and people 
are now just blaming deformities on injectables.   
Other participants believe that harm to the baby only results if the woman uses 
contraceptive injectables when she conceives.  A community leader [FGD 2] explains: 
 It is at times true that injectables can cause deformation, but only if the mother 
started using this method after she conceived and she did not inform the health 
provider about this. … for us to know that one has conceived, it is only if she 
attends… or if a pregnancy test is done on her … otherwise contraceptives with 
hormones can cause someone to give birth to a child with deformity such as one with 
a finger missing, one eye, [and] combined vital organs.  
 
Other fears of injectables expressed in a little less half of the FGDs included:  death, 
decreased weight, and drowsiness or laziness.  Drowsiness or laziness which results in 
trouble performing physical work was a major complaint of husbands in both FGDs and 
some current users, long-term users and mothers-in-laws.  One husband laments, “What I 
dislike about it [injectables] is that it makes women lazy. Because they take something that 
does not suit their bodies from Depo-Provera injection. This is what it brings, and again she 
cannot do any difficult work.”  Another husband in that same FGD explains his view on the 
situation: 
 It looks like this people [who use injectables] sleep a lot because of their weight 
[gained by using injectables]. If there could be any way through which this weight 
could be reduced, then I think it would really help them [injectable users] because for 
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sure those who use Depo tend to add weight extremely making them very lazy. She 
cannot do anything, she can only sit and watch. So it’s you the husband who will be 
working for her. And this is the reason they [injectable users] become weak.  
 
Suggestions for improving continuation 
Participants in all FGDs were asked for their advice to improve contraceptive 
continuation in their community.  The groups containing male participants (husbands and 
community leaders) had many more suggestions than the groups containing female 
participants.  Service providers had very few suggestions other than for the provision of a 
constant supply of injectables to the clinics and a reduction in the cost of injectables.  The 
most common suggestion across all groups (13 out of the 14 FGDs) was to disseminate 
correct information about injectables or family planning in general to the community.  Six 
groups specifically suggested that efforts focus on disseminating information about the 
advantages and disadvantages of injectables. Three groups suggested that only the 
advantages of injectables be discussed. And two groups suggested that efforts focus on 
dispeling myths about injectables.  The following people or places were mentioned as ideal 
sources to disseminate this information:  chief barazas (community-wide meetings), health 
providers and facilities, mass media channels (especially radio), community health workers, 
and other community gathering places (church, funerals).  Participants from seven FGDs 
suggested that current injectable users could serve as role models to foster continuation in 
their community.   
Male involvement was suggested to improve contraceptive continuation in five FGDs.  
Participants recommended that men be involved during the decision making process of 
starting FP and selecting a method so that they know about the advantages and potential 
side effects of injectables.  A husband describes how men in this community can prevent 
women from continuing to use contraception: 
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 …even if you stop or even if they are still using [injectables], it’s the men who stop 
them [women] from using and also stopping them from going to the family planning. 
So expect that women have not refused to use family planning, they really want it. 
But it’s their husbands that make them not to go for it. Husbands should be taught 
more than what should be taught to the women about family planning methods. 
 
One community leader [FGD 2] advises: 
Men also should be invited so that they are taught about the advantages of the 
injectables or family planning in general because in most cases women are taught 
about these things as men are left behind. This is also a problem. So those who 
have the ability to organize trainings should also invite men so that they also get the 
information required. Especially on the advantages of family planning or using the 
injectable, so that these men, who say there is a problem they can come and get to 
know the real advantages and disadvantages. 
 
Governmental involvement in terms of disseminating family planning information, 
training providers, and maintaining a constant supply of injectables was suggested in four 
FGDs.  Participants in four FGDs suggested that encouragement be provided to current 
users to help them continue using injectables.  Some of the participants in the FGDs with 
husbands and mothers-in-laws recognized their influential role in contraceptive continuation, 
as well.  One mother-in-law [FGD 1] noted, “Yes, we can educate them, we as parents who 
have given birth and we have experienced dificulties in this world we can encourage them to 
use injectables because of high economic standards which have increased rapidly.”  
Discussion 
Numerous reasons influence whether women who want to space or limit births 
discontinue using injectables in Nyando District.  These reasons are logistical, social, 
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medical or a combination of all three.  A salient logistical reason uncovered in these data is 
the pervasive problem of commodity stock outs.  If injectables are not available at the FP 
clinics, women in this community discontinue because they can not afford to purchase the 
product elsewhere.  Other major logistical barriers lie within the clinics themselves.  
Unnecessary and sometimes incorrect provider and/or clinic restrictions inhibit women from 
receiving injections.  Three clinic restrictions for injection and re-injection found in these 
FGD data are particularly worrisome and include parity, hypertension and menstruation 
requirements.  The World Health Organization (WHO)’s medical eligibility criteria for 
contraceptive use do not restrict contraceptive injectables for nulliparious women, 
adolescents or those with hypertension.[28]  Progestin-only injectables, which are the 
predominant injectables used in Kenya, do not contain estrogen and therefore do not cause 
any of the cardiovascular complications associated with pill use.[14] Women with adequately 
controlled hypertension or mild to moderately elevated blood pressure can continue using 
progestin-only injectables.[29]  Finally, a simple checklist has been found to be effective at 
ruling out pregnancy and would allow nonmenstruating women immediate access to 
contraception. [30] This checklist has been endorsed by both the WHO and the Kenyan 
Ministry of Health Division of Reproductive Health.[31] 
Social reasons also lead to premature discontinuation of injectables.  Women in 
Nyando District do not always have control over the use and continued used of 
contraception because such decisions are often made by their husbands or other influential 
people in their community and household.  Much of the opposition husbands hold towards 
the use of injectables or other methods stem from a low level of knowledge regarding side 
effects. Cultural beliefs about gender, sex and fertility also have an important role in 
discontinuation behavior.  In this patriarchical society, polygamy and ritual sex surrounding 
social and agricultural events is practised.[32, 33]   Fulfilling “conjugal duties” and bearing 
multiple children are critical parts of a married woman’s duty.  Contraception that reduces a 
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woman’s libido and willingness to be an active sexual partner puts strain on marriages in the 
Luo community.  Male and female FGD participants were well aware of this constraint of 
injectables, but offered numerous solutions to the problem, too.  Participants suggest 
involving men in FP educational efforts might make them understand the advantages of FP, 
the potential side effects of injectables, and be more understanding if their wife experiences 
a side effect such as lowered libido. 
Not surprisingly, medical reasons for discontinuation in this study were numerous.  
Similar to previous research, common side effects of injectables reported included weight 
gain and menstural changes.  What is more interesting are the common side effects and 
health-related fears that the participants reported that are not found in medical literature on 
injectables like back aches, infertility, delivering a deformed baby, high blood pressure and 
drowziness.  Educational and counseling efforts in this community should be tailored to 
address these community-specific concerns. 
This study did not include discontinuers as a specific subgroup.  This seeming 
oversight was actually by design since it is very diffult to identify and recruit discontinuers in 
the rural community in this study.  Furthermore, it was expected and found to be true that 
many of the long-term users had discontinued using injectables in the past.  However, the 
analysis would have been strengthened had we been able to include discontinuers as a 
separate group.   
In the next phase of this research, we will distill and disseminate through local radio  
critical information on injectables to see whether this reduces discontinuation more in an 
experimental area than in a comparison area. 
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Table 2.1: Number of FGD participants per group 
Categories of participants Number of participants 
Current injectable users group 1 10 
Current injectable users group 2 12 
Current injectable users group 3 11 
Current injectable users group 4 8 
Husbands of injectable users group 1 11 
Husbands of injectable users group 2 9 
Mothers-in-law of injectable users group 1 8 
Mothers-in-law of injectable users group 2 9 
Service providers group 1 8 
Service providers group 2 10 
Community leaders group 1 8 
Community leaders group 2 9 
Long-term injectable users group 1 11 
Long-term injectable users group 2 11 
Total number of FGD participants 135 
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Table 2.2: Codes expressed in two or more groups 
Code Total frequency 
(range 2-14) 
Frequency by 
respondent type 
(range 1-6) 
Emergent (e) 
versus 
Predetermined (p) 
code 
Logistical reasons 
Clinic restrictions 9 5 e 
Stock outs of family planning (FP) 
method 8 
 
5 
 
p 
Lack of knowledge 8 4 e 
Lack of cash to purchase FP method 
or services 7 
 
4 
 
p 
Other health issue leads to 
discontinuation 4 
 
4 
 
e 
Problems getting to clinic 3 3 p 
Social reasons 
Covert use of FP method 13 6 e 
Cultural beliefs about gender roles 12 6 e 
Husband (HUS) general opposition 12 6 p 
Both partners decide to use FP 
method together 11 
 
5 
 
e 
HUS wants more children 10 4 e 
Marital problems: Decreased libido 9 6 e 
Decreased libido leads to suspicion 
of women being unfaithful 8 
 
5 
 
e 
Religious opposition 8 5 e 
Cultural beliefs:  general 7 5 e 
Method use associated with 
prostitution 7 
 
5 
 
e 
Decreased libido leads husband 
seeking new sexual partner 5 
 
4 
 
e 
Marital problems: Changes in 
bleeding 5 
 
4 
 
e 
HUS preference for male children 5 3 e 
Marital problems:  Discovery of 
covert use 5 
 
3 
 
e 
Cultural beliefs about sexual 
intercourse 4 
 
4 
 
e 
Cultural beliefs about menstruation 4 3 e 
Mothers-in-law (MIL) general 
opposition 3 
 
3 
 
e 
Other (not HUS or MIL) general 
opposition 3 
 
3 
 
e 
Increase population in community 3 2 e 
MIL wants more children 2 2 e 
Other (not HUS or MIL) wants more 
children 2 
 
2 
 
e 
Medical reasons 
Sickness or poor health or side effect 
not specified 14 
 
6 
 
e 
Infertility 13 6 p 
Disliked decrease bleeding 12 6 p 
Disliked weight gain 12 6 p 
Deformed baby 11 6 p 
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Back aches 10 6 e 
Increased bleeding 10 5 p 
High blood pressure 9 5 e 
Irregular bleeding or spotting 9 5 p 
Disliked lower libido 8 6 p 
Abdominal bloating/discomfort 8 5 p 
Death to user 6 5 e 
Headaches 6 5 p 
Decrease in weight 6 4 e 
Drowsy or laziness or trouble doing 
work 6 
 
4 
 
e 
Delayed return to fertility 5 4 p 
Liked weight gain 5 3 e 
Dizziness or blurred vision 4 4 p 
Increased appetite 4 3 p 
Liked decrease bleeding 4 2 e 
Decreased weight associated with 
HIV or AIDS 3 
 
3 
 
e 
Mood changes 3 3 p 
Nausea 3 3 p 
Changes in vaginal secretions 2 2 p 
Complications when giving birth 2 2 e 
Fever 2 2 e 
Liked lower libido 2 2 e 
Varicose veins 2 2 e 
Bleeding changes (not specified) 2 1 p 
 
CHAPTER 3. Rates and predictors of contraceptive discontinuation in two districts in 
western Kenya
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Abstract 
Contraceptive discontinuation is high in Kenya—25% of family planning (FP) users 
discontinue within 12 months, despite having FP needs.  Continuation rates were measured 
in two districts in Kenya before implementing a campaign to increase contraceptive 
continuation.  Prospective data were collected over 9-months to:  (a) describe factors which 
predict occurrence and timing of contraceptive discontinuation among first-time 
contraceptive injectable users, and (b) determine if rates and predictors of discontinuation 
differ between districts. This study incorporated novel time-dependent attitudinal and 
motivational factors. 
The following predicted discontinuation: side effects or health concerns, nervousness 
about using contraception, no previous use of modern FP, unmarried at study enrollment, 
preferring more privacy during FP appointment, and paying more for FP services.  
Associations between predictors and discontinuation differed between the districts, as did 
rates of discontinuation.  Findings suggest a tailored approach for interventions to increase 
continuation and that FP services address side effects and health concerns. 
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Background 
Globally, contraceptive use is increasing. However, discontinuation rates are high, 
especially in the developing world. [1, 2]  According to the 2003 Kenya Demographic and 
Health Survey (DHS), 33% of married women were using a modern method, but 25% of all 
contraception users discontinued within 12 months of beginning use, despite still being in 
need of family planning (not due to desire for pregancy or reduced risk to pregnancy). [3] 
Contraceptive discontinuation in Kenya has increased since the 1998 DHS and the increase 
has been attributed to the relatively high discontinuation rates for pills and injectables. [3,4] 
The predominant method used in 2003 was injectables (14% of currently married women), 
followed by the pill (8%).  Despite its popularity, 21% of injectable users discontinue use of 
the method within 12 months of starting, despite still having family planning (FP) needs. 
FP service-related factors, including quality of care, are thought to be associated with 
contraceptive discontinuation.[6]  However, studies of quality of care have not shown large 
effects on discontinuation rates.[7-10]  Consistent determinants of discontinuation include:  
type of method used, side effects, age (younger women are more likely to discontinue than 
older women), fewer living children, fertility intentions (women wanting to increase space 
between their children are more likely to discontinue compared with women who have 
completed childbearing), and a change in marital status (women who experience a change 
in martial status are more likely to discontinue).[2]  Discontinuation appears to be less 
consistently associated with the number of methods available [7], socio-economic factors 
including education [1,2,11], urban-rural residence [1], husband’s disapproval [12], cost or 
lack of access to the method [7,11]. 
In Kenya, side effects are the most commonly stated reason for discontinuation,  
predominantly associated with pills and injectables.[3] Among the discontinuations 
reported in the five years before the 2003 DHS, the percentage that were attributed to side 
effects increased from 20% in 1998 to 25% in 2003.  In 2003, 13% of currently married 
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women not currently using a method reported that they did not intend to use a method in the 
future because of fear of side effects.  The proportion increased to 20% for women under 30 
years of age. 
A four-year prospective quasi-experimental study is currently being conducted to 
encourage contraceptive continuation by developing, implementing and evaluating a 
communication campaign intended to increase continuation rates among contraceptive 
injectable users in Nyando District, Kenya.  This study is the first of its kind to utilize a 
communication campaign to increase contraceptive continuation rates. If proven effective, 
the intervention strategy could be applied in other settings around the world and could have 
significant public health impact.  
The evaluation for the intervention study uses an untreated comparison group design 
with independent pretest and posttest samples. [5] Pre-intervention data on continuation 
rates in the treatment (Nyando District) and comparison (Mumias District) sites were 
collected before the campaign was introduced and are the focus of this paper.  The goals of 
this paper are to:  (a) describe the factors which predict the occurrence and timing of 
contraceptive discontinuation among first-time contraceptive injectable users still in need of 
FP in the two study districts before implementation of the communication campaign, and (b) 
determine if the rates and predictors of discontinuation differ between the districts before 
implementing the communication campaign. 
Significance 
Building on the literature discussed above, we hypothesize that predictors of 
discontinuation in the two districts in this pre-intervention study will be similar to those found 
in other locations around the world.  This study extends existing literature by measuring 
several factors which have not been included in most previous studies of contraceptive 
continuation, but that health behavior theories such as the Health Belief Model, Theory of 
Planned Behavior, and Social Cognitive Theory suggest may be important determinants of 
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continuation behavior. These theories have been shown to predict numerous other health 
behaviors and therefore should be explored for their potential effect on contraceptive 
continuation behavior. [13] Some of these novel factors include motivations to avoid 
pregnancy, confidence in using contraception, and a woman’s decision-making power within 
the sexual relationship.  A study conducted in Honduras found contraceptive users’ attitudes 
about childbearing vary over time, and also identified an association between fertility 
motivations and contraceptive discontinuation. [14] Unlike the Honduras study which 
measured attitudes at baseline and one-year later, the attitudinal factors in this current study 
were measured up to four times over the course of the study.  The advantage of repeated 
measurements of a variable over time is the opportunity to include a more proximate 
measurement of the respondents' attitude/behavior/condition to the time of the event (i.e., 
discontinuation) and reduce potential recall bias.   
In sum, this study offers the opportunity to investigate the effects of previously 
explored and novel factors on continuation behavior. Finding that the factors that influence 
discontinuation in the study districts are similar to those found in previous studies would 
provide support for universal (versus local) reasons for discontinuation.  It is important to 
note that finding that a particular factor is “statically significant” at one site but not at the 
other is not the same as determining that the associations of that factor with the outcomes 
differ between the two sites. However, if similar reasons for contraceptive discontinuation 
are found in diverse samples, public health practitioners could develop and recommend 
universal or template intervention for increasing continuation. 
The findings from this study may suggest characteristics of women in this population 
that predict discontinuation of FP methods while still in need.  Given limited funds for FP, 
public health practitioners could use this information to target women likely to be most at-risk 
for premature discontinuation with efforts to increase contraceptive continuation and reduce 
unintended pregnancies. 
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Methods 
Five hundred new injectable users from clinics in two districts in Kenya (1,000 
participants in total) were enrolled in the pre-intervention study beginning April 2008.  
Participants were re-interviewed every three months over a nine-month period.  We focused 
on injectables because they are the most popular contraceptive method in Kenya.  Two 
comparable sites in the western region of Kenya were selected based on requirements for 
the intervention study as follows:  Nyando District (treatment site) was selected because it is 
located in Nyanza Province, which has a high HIV prevalence rate (15%) compared to the 
national average (7%). [15] This situation has led to increased focus to improve reproductive 
health services in the region by both the government and non-governmental organizations. 
Mumias District (comparison site), located in Western Province, borders Nyanza to the north 
and does not share media channels which would be used for the intervention in Nyando.  
Mumias has an HIV prevalence rate of 6%. [15]   
Sample selection  
A list of Ministry of Health (MOH) clinics that provide contraceptive injectables to 
women was obtained for each study district.  The number of clinics enrolled in each site 
depended on the number of new injectable users attending the clinics the previous year.  
Sample size for the pre-intervention study was based on the application of survival analysis 
for the intervention study1.  Given that 500 new injectable users needed to be recruited in 
each site during a three-month time period, clinics with the highest average number of 
                                                          
1
 A one-sided log rank test with an overall sample size of 912 participants (456 in the treatment group 
and 456 in the comparison group) achieves 90% power at a 0.05 significance level to detect a 
difference of 0.1 between 0.6 and 0.7--the proportions surviving in the comparison and treatment 
groups, respectively. Assuming exponential survival times, this corresponds to a constant hazard 
ratio of 0.7. The proportion of participants lost during follow-up was assumed to be 0.15.  An effect 
size of 10% was assumed for the intervention study based on a review of previously evaluated 
reproductive health mass media and counseling interventions. 
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injectable clients (new and returning) were identified from the entire list of MOH clinics.  A 
random sample of 10 clinics from each district was selected for inclusion in the study from 
the list of clinics with high injectable client flow. 
All new injectable users who attended the study clinics during the three-month 
enrollment period were invited to join the pre-intervention study.  The women were not 
required to be first time contraceptive users, but at enrollment, they had to be first time users 
of contraceptive injectables.  Participants also had to be 18 years or older and residents of 
one of the two study districts.  
Data collection  
Baseline interviews for the pre-intervention study were conducted at the conclusion 
of participants’ FP appointment in a location inside or just outside of the clinic. The three 
follow-up interviews were conducted at the participants’ homes or another location 
designated by the participant every three months (a few days after the study participants 
would have received their next injection should they desire re-injection).  Trained female 
research assistants administered quantitative questionnaires at each assessment period 
measuring demographic variables, time-invariant and time-dependent factors which may 
influence discontinuation, and the date of discontinuation of a modern FP method (after 
baseline).   
Ethical considerations 
Written informed consent was obtained from all study participants.   Participants 
were given 200 Kenya Shillings (approximately $3.00) for their time at each interview.  The 
study was reviewed and approved by three ethical committees:  Family Health International 
(FHI)'s Protection of Human Subjects Committee, the Kenyatta National Hospital Ethics 
Review Committee and the University of North Carolina at Chapel Hill Institutional Review 
Board. 
Hypotheses 
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1.  Based on existing literature the following factors are hypothesized to predict 
discontinuation while still in need of FP in the study districts: 
• Experience of a side effect or report of a health concern  
• Fear of side effects/health concerns  
• Age (with younger women being more likely to discontinue than older women) 
• Fewer living children 
• Fertility intentions (with women who want to space their children being more likely to 
discontinue compared with women who have completed childbearing) 
• Change in marital status (women who get married during the study are more likely to 
discontinue than women who do not change their marital status or get divorced) 
2.  The associations between predictors and contraceptive discontinuation will be the same 
in the two districts. 
3.  Survival curves for time to discontinuation of contraception while still in need will not be 
different in the two districts.   
Dependent variable 
First discontinuation of a modern contraceptive method while still in need of FP is the 
dependent variable and the "event" in the survival analysis models.  This variable was 
constructed by asking participants about their continued FP use during the follow-up 
interviews.  Participants who reported they continued using injectables or switched to any 
other modern FP method will be considered “continuers.”  Following the definition used by 
the DHS, the following contraceptive methods are considered modern methods:  female 
sterilization, male sterilization, IUCD, implants, injectable contraceptives, oral 
contraceptives, male or female condom, diaphragm/spermicides, or lactational amenorrhea.   
Participants who did not continue using injectables and did not switch to another modern 
method were asked why they discontinued.  Reasons for discontinuation were used to group 
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women into one of two categories:  “no longer in need” or “still in need” of FP. Based on 
standard DHS definitions, the following reasons were considered as "still in need:” 
discontinued because became pregnant while using method (method failure), 
husband/partner disapproved, health concerns, side effects, lack of access/too far, costs too 
much, inconvenient to use, or wanted a more effective method, but did not switch to another 
modern method.  Participants who discontinued while still in need of FP were considered to 
have experienced an “event” in the survival models.  Women were censored at the point at 
which they were lost, were no longer in need, or discontinued from the study.   
At the time of the study, DMPA users were instructed to return to the clinic for re-
injection every three months, and FP protocols in Kenya allowed repeat DMPA injections to 
be given as late as 14 weeks or 98 days after the previous injection. [16] The duration of 
modern method use in the study was calculated, using the smallest of the following values: 
a. Days that elapsed between date of last interview and enrollment date (Date 
of the last interview minus the enrollment date); 
b. Days covered by a modern contraceptive method:  the later of the date of last 
injection plus 98 days or date when stopped using other modern methods, 
minus the enrollment date; 
c. 294 days (The maximum number of days covered by a modern contraceptive 
during the study, which is based on 98 days of protection from one DMPA 
injection multiplied by three follow-up interviews). 
Independent variables   
Descriptions of the independent variables considered in this study are found in the 
Appendix.  Several of the independent variables are time-dependent, meaning that 
respondents provided answers to the same questions up to four different times (at baseline 
and three follow-up interviews).  The variable items came from other questionnaires such as 
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the DHS or were created specifically to measure constructs suggested by health behavior 
theories.  The data were structured using the counting process form of a Cox model [17].  
Three separate exploratory factor analyses (EFA) were conducted in Mplus Version 
5.2 to create several independent variables for use in the survival analysis models. [18] The 
purpose of EFA is to identify a more parsimonious conceptual understanding of a set of 
measured variables by determining the number and nature of common latent factors that 
account for the pattern of correlation among the variables.[19]  The first EFA consisted of 
time-dependent variables intended to measure motivations to avoid pregnancy; the second 
was intended to measure the construct of decision making power regarding contraceptive 
use and health care; and the final was intended to measure perceived quality of care at the 
last FP appointment.    
EFA is based on the common factor model which defines measured variables as 
linear functions of common factors. [20] Many of the variables included in the factor 
analyses for this study are binary or ordinal.  Common factors have continuous scales, and 
binary measured variables cannot be a linear function of continuous common factors.  This 
problem is addressed by obtaining polychoric correlations. [21] Since the EFAs contained a 
combination of categorical and continuous dependent variables, the weighted least-square 
parameter estimator was employed using a diagonal weight matrix with standard errors and 
a mean-adjusted chi-square test statistic that uses a full weight matrix. The Crawford-
Ferguson oblique oblimin rotation was used because we expect the factors to be correlated.  
Missing data were handled using a pairwise present approach.   Correlations between 
repeated observations from the same person were accounted for in the models using a 
robust variance estimator. This approach enables all of the measured variables for a given 
construct, irrespective of scale, to be put into the same EFA.  Variables were eliminated 
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from the EFA to enable the model to converge2 and the model was re-run.  The variables 
eliminated from the EFAs were assessed individually in the bivariate analyses for their 
inclusion in the final survival model. 
Data from one district (the district with the least missing data) were used to identify 
the number and nature of the factors for the other district.   This assumes the factor structure 
is the same in the two districts, an assumption that was validated by conducting a separate 
EFA using the data from the second district.  The scree test was used to determine the 
number of factors to retain.  This test involves examining the plot of eigenvalues and looking 
for the last substantial drop in the magnitude of the eigenvalues. [19] The number of factors 
above this point suggests the number of factors to be retained.  Given the goal of these 
factor analyses is to create independent variables which can predict the outcome, the 
number of factors decision will also be influenced by the amount of variance captured by the 
factors.  Finally, the factors retained must make sense and be interpretable.  Problematic 
items which violate Thurstone's criteria for simple structure (e.g., low loadings on all factors, 
numerous high cross loadings, and free standing) were eliminated and the analysis re-run 
until a parsimonious solution was obtained. [20] 
The estimated factor scores were obtained using the exploratory structural equation 
model (ESEM) feature of Mplus Version 5.2. [18] For the first site this approach required the 
user to only specify the number of factors for the model.  For the second site each 
parameter was fixed using the parameter estimate obtained from the ESEM from the first 
site, and thus measurement invariance is assumed.  By using the same variables and same 
scoring values for both sites the resulting factor scores from the two sites are comparable 
and intended to measure the same constructs. 
Missing data 
                                                          
2
 Polychoric correlations could not be obtained due to sparseness among the bivariates for these 
variables. 
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Missing data can lead to bias in parameter estimates and invalid results. [21] The 
variable measuring household income was omitted from the analysis because of a high 
degree of missingness (greater than 20%) in both sites.  The default in many statistical 
programs is deletion of cases with missing data.  This approach has been found to lead to 
bias, reduction of sample size and power, and is not preferred.  We used multiple imputation 
(MI) to handle missing data for the independent variables. Imputation techniques involve 
replacing missing data with estimates based on values of other variables in the data set.  
The advantage of multiple imputation over single imputation techniques is that MI adds 
variability to the process by creating different estimates for a single missing datum resulting 
in unbiased estimators and standard errors.  MI assumes that data are MAR, but it can be 
used to handle systematic patterns of missing data and is robust to violations of non-
normality of the variables.  Specifically, MI was conducted using the Markov chain Monte 
Carlo method with a single chain to create five imputations. The posterior mode, the highest 
observed-data posterior density, with a noninformative prior, is computed from the 
expectation-maximization (EM) algorithm and is used as the starting value for the chain. 
When missing values do not exceed 20% Rubin suggests that 3-5 repetitions are sufficient. 
[22] Then, each of these completed datasets was separately analyzed. Finally, the results of 
these separate analyses were combined to produce final parameter estimates and other 
model results. 
Data analysis 
Data analysis was conducted using SAS software, Version 9.2 of the SAS System 
for Windows. [23] Survival analysis methods were used to test the three hypotheses.  Tests 
were considered statistically significant if p<.05. 
For the first and second hypotheses, Cox regression models were fit separately for 
each study district. [24, 25] The exact likelihood method was used to handle the ties.  
Multiple tied event times are expected in these data.  In reality, there is a window of many 
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days during which women can receive their next injection and still be protected against 
pregnancy.  It is therefore reasonable to suppose that ties are the result of imprecise 
measurement of time and that there is a true (but unknown) ordering among respondents 
that have the same nominal durations.  To control for clustering expected at the clinic level, 
a sandwich estimator was used to obtain robust standard errors.   
All study participants were first-time contraceptive injectable users, so time at risk for 
discontinuation started 98 days after their first injection.   Participants who discontinued 
within 9 months had the event of interest, while those who either dropped out before 9 
months or did not discontinue by 9 months were right censored. It is possible that some of 
this censoring is informative (e.g., those who dropped out of the study earlier may have 
been more likely to have discontinued).  Informative censoring could lead to biases because 
the reason for censoring may be related to the outcome.  One method of correcting for 
informative censoring is to include in the model all factors that affect both event 
(discontinuation) times and censoring times.  Given that it is impossible to know all of these 
factors sensitivity analyses were conducted.  The final models were re-run at the extreme 
where those lost to follow-up, and therefore censored in the primary survival analysis, were 
re-coded to experience an event (discontinuation) at the time of censoring. 
Each independent variable was examined in bivariate analyses (i.e., a survival model 
with only one predictor) to see if it was significantly associated with the dependent variable.  
This procedure was conducted separately for each study district.  Given the long list of 
independent variables, only those which were significant in the bivariate analyses in either 
district and those listed under hypothesis 1 were entered into the final models for both 
districts to predict time to first discontinuation while still in need of FP.  Backwards model 
reduction was then used to eliminate variables that were not statistically significant in either 
district until the final models contained only significant predictors for either district. [26] In 
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order to compare the districts for the second hypothesis, both final models must be the 
same.   
The first hypothesis was assessed by qualitatively comparing the list of significant 
predictors of the dependent variable (time until discontinuation while still in need of 
contraception) in the two models to those found in previous studies predicting contraceptive 
discontinuation.  The second hypothesis was evaluated by comparing the parameter 
estimates between the two models using 95% confidence intervals. 
The third hypothesis required comparison of the two study districts with respect to 
the distribution of time until discontinuation while still in need of contraception.  To evaluate 
this hypothesis survival curves were estimated and compared for each district using Kaplan-
Meier plots and a log-rank test, stratified by district.   
Results 
There were 501 women enrolled into the study in Mumias District and 505 women 
enrolled in Nyando District.  Sixty five participants from Mumias and 71 participants from 
Nyando were eliminated from the data set because they did not have any follow-up data and 
would be eliminated from the survival analysis models by list wise deletion.  In Mumias, no 
differences in the time invariant (baseline) variables were found between those who 
where eliminated because they had no follow-up data compared to those who remained 
(data not shown). In Nyando, those eliminated were less likely to have completed secondary 
or higher education, more likely to be a spacer (versus a limiter), and were more likely to be 
younger than those who remained in the data set.  In Nyando, three participants were 
missing their baseline questionnaires and were also deleted.  After these deletions, 436 
participants remained in the Mumias data set who contributed a total of 970 records and 431 
participants remained in the Nyando data set who contributed a total of 876 records.     
Two percent of women in Mumias (n=9) and in Nyando (n=10) switched to another 
modern method during the study. Out of the 436 participants in Mumias, 66 (15%) 
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discontinued using a modern contraceptive method while still in need of FP during the study 
(i.e., the event in the survival analysis).  Out of the 431 women in Nyando, 34 women (8%) 
discontinued during the study.  The average number of days of continuous use of modern 
method during study was 212 days in Mumias and 201 days in Nyando.   
In Mumias, 163 participants (37%) were lost to follow-up and in Nyando 250 (58%) 
were lost to follow-up.  In both sites those lost to follow-up were more likely to be from urban 
(versus rural) residences compared to those who remained in the study until the end of data 
collection (data not shown).  In Mumias, those lost were also more likely to be younger than 
those who were not lost.  In Nyando, those lost reported a greater number of contraceptive 
methods discussed by the provider during enrollment compared to those who were not lost.  
No other differences in the time invariant (baseline) variables were found between those lost 
to follow-up and those who remained in the study. 
Descriptive information for measures 
Descriptive statistics for the time invariant (baseline) variables are shown in Tables 
3.1 and 3.2.  In both districts, the average age of study participants was 25 years.  Most 
participants were members of the majority ethnic group in their respective districts (Luhya in 
Mumias and Luo in Nyando), Christian, and married at the time of enrollment in the study.  
Approximately one in five of the participants had used a modern contraceptive method (not 
injectables) prior to enrollment into the study.  On average, women in both districts had 
three children.  Twenty seven percent of Mumias participants reported that they did not want 
any more children at study enrollment compared to 34% of Nyando participants. 
Descriptive statistics for the time-dependent variables are shown in Tables 3.3 and 
3.4.  For these variables participants contributed multiple records over the study.  Seven 
percent of Mumias participants and four percent of Nyando participants experienced a 
change in marital status at least once during the study.  Forty-two percent of Mumias 
participants and 33% of Nyando participants expressed a fear of side effects or health 
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concerns about the contraceptive method they were using.  Thirty-nine percent of Mumias 
participants and 30% of Nyando participants experienced at least one side effect/health 
concern while using injectables during the study.  While participants reported up to six 
different side effects or health concerns experienced during the study, the average number 
of side effect/health concerns experienced was one in both districts.  Exposure to FP 
information in both communities was high; 85% and 97% of participants in Mumias and 
Nyando, respectively, were exposed to at least one message in the community during the 
study (data not shown).  The majority of participants in Mumias (86%) and Nyando (88%) 
felt “very confident” in their ability to successfully use contraception to avoid pregnancy.   
Sixteen percent and 13% of participants in Mumias and Nyando Districts, 
respectively, reported problems accessing injectables over the study.  These problems 
included having to come to the FP facility more than once to obtain injectables or not being 
able to obtain injectables at all.  However, most participants in both districts reported they 
were able to ultimately receive their method of choice.  Eighty-three percent of participants 
in Nyando felt there was enough privacy during their last FP appointment compared to 50% 
of participants in Mumias.  Ninety-five percent of participants were “very satisfied” with how 
they were treated by the provider in Nyando compared to 86% in Mumias.  Sixty-four 
percent of Nyando participants compared to 57% of Mumias participants had all their 
questions about the FP method answered by providers.  The average cost of FP services, 
including one-way transportation costs to the appointment, was 42 Kenyan Shillings (USD 
0.5) in Nyando compared to 53 Ksh (USD 0.7) in Mumias. 
Full survival models 
All of the variables in Tables 3.1-3.4 with the exception of the outcome (experienced a 
discontinuation) and lost-to-follow up were examined in bivariate analyses.  The first full 
survival model for each district contained 24 predictors (data not shown), which included the 
independent variables significantly associated with the outcome, those listed under 
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hypothesis 1, and the interaction of baseline marriage with the change in martial status 
variable (this interaction term was included to detect the direction of marital status change).  
After backwards model reduction, eight predictors remained in the second model for each 
district (data not shown).  After a third round of backwards reduction, the final model for both 
districts contained six predictors (see Tables 3.5 and 3.6).   
We failed to find evidence that any of the factors hypothesized to predict discontinuation, 
except experiencing side effects or health concern, predicted discontinuation in both of the 
two study districts.  In Mumias, the factors that predicted discontinuation included: 
• Experiencing a greater number of side effects or health concerns 
• Being nervous about using contraception 
• Having never previously used a modern contraceptive method 
• Preferring more privacy during the appointment 
In Nyando, the factors that predicted discontinuation included: 
• Experiencing a greater number of side effects or health concerns 
• Being nervous about using contraception  
• Paying more for FP services 
• Not being married at enrollment  
The results assessing whether the associations between predictors and contraceptive 
discontinuation were the same in the two districts (hypothesis 2) are presented in Table 3.7.  
Hypothesis 2 is rejected because the associations between predictors and contraceptive 
discontinuation differed between the two districts.  Specifically, the associations differed in at 
least three respects: 
• Nyando women who paid more for FP services were more likely to discontinue 
compared to Mumias women who paid more for services 
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• Nyando women who were not married at enrollment were more likely to discontinue 
compared to Mumias women who were not married at enrollment 
• Mumias women with previous contraceptive use were less likely to discontinue 
compared to Nyando women with previous contraceptive use 
Figure 3.1 displays the Kaplan-Meier plots to evaluate hypothesis 3, that the survival 
curves for each district will not differ.  The chi-square for the 1 degree of freedom log-rank 
test was 9.6330, p = 0.0019.  Hypothesis 3 was rejected because the survival functions for 
time-to-discontinuation of contraception while still in need were significantly different in the 
two districts.  Specifically, time-to-discontinuation in Nyando District was slower compared to 
time-to-discontinuation in Mumias District.  For Mumias participants, 8% discontinued by 98 
days, 14% by 196 days and 24% by 294 days.  For Nyando participants, 3% discontinued 
by 98 days, 7% by 196 days and 15% by 294 days.  The Kaplan-Meier estimates of 
discontinuation probability only include those people still at risk for the event at the time of 
each event.  
Sensitivity Analyses 
The three hypotheses were assessed again in sensitivity analyses where censored 
cases in the primary analysis were re-coded to experience a discontinuation immediately 
after censoring.  These sensitivity analyses represent a “worst case scenario” and the truth 
is probably somewhere in between the two analyses.  In both districts, the factors that 
predicted discontinuation (Tables 3.8 and 3.9) included: 
• Having never previously used a modern contraceptive method 
• Not being married at enrollment  
Hypothesis 2 can not be rejected in the sensitivity analysis because no differences were 
found between the associations between predictors and contraceptive discontinuation in the 
two districts (see Table 3.10).   
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Figure 3.2 displays the Kaplan-Meier plots to evaluate hypothesis 3 in the sensitivity 
analysis.  The chi-square for the 1 degree of freedom log-rank test was 9.7821, p = 0.0018.  
Hypothesis 3 was rejected because the survival functions for time-to-discontinuation of 
contraception while still in need were significantly different in the two districts.  Time to our 
revised definition for discontinuation in Mumias District was slower compared to time-to-
discontinuation in Nyando District.  For Mumias participants, 20% discontinued by 98 days, 
47% by 196 days and 55% by 294 days.  For Nyando participants, 25% discontinued by 98 
days, 54% by 196 days and 67% by 294 days.  It is important to note that these results are 
influenced by the high and differential lost-to-follow-up rates in Mumias (37%) and Nyando 
(58%) Districts.  The pattern of loss was also different between the two districts—the 
Nyando sample lost a greater proportion of its respondents earlier in the study compared to 
Mumias.  Thirty-five percent of those lost to follow-up in Nyando were lost after the first 
follow-up interview compared to 21% in Mumias (data not shown). 
Discussion 
The demographic characteristics of the study participants in the two districts appear 
similar for most of the variables examined.  Surprisingly, approximately a third of participants 
in both districts say they do not want any more children yet participated in this contraceptive 
injectable study.  A practice recommendation stemming from this finding is to help those 
desiring to limit childbearing to use longer acting or permanent methods.  Looking at the 
pattern of responses across the two districts for the variables measuring quality of care 
received at the last FP appointment, participants in Nyando District appear to have higher 
satisfaction with the quality of care received at their last FP appointment compared to those 
in Mumias District.  However, almost all participants in both districts said they will return to 
the same facility for their next FP appointment, indicating either that the quality is not that 
poor or there is a lack of alternative places to obtain FP services in their community.  
Despite the difference in perceived quality of care, the majority of participants in both 
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districts continued using injectables over the course of the study.  Prospective 9-month 
discontinuation rates for first-time injectable users in this study were 24% in Mumias and 
15% in Nyando.  Nationally, 21% of injectable users discontinue use of the method within 12 
months of starting, despite still having FP needs.  While the rates found in this study are not 
directly comparable to the 12-month discontinuation rate calculated retrospectively from 
calendar data in the 2003 DHS, it is interesting to note that they are similar to the national 
rate. 
As expected, experiencing side effects or health concerns predicted discontinuation 
of a modern contraceptive method while still in need of FP in both districts.  None of the 
other factors hypothesized to predict discontinuation based on review of the FP literature 
was supported in these data.  The other reason for discontinuation common across the two 
districts was the respondent being nervous about using contraception.  While most previous 
research has not found strong effects for indicators of quality of care on discontinuation, in 
this study two indicators of quality of care—not having enough privacy during the FP 
appointment and higher cost of FP services— predicted discontinuation in Mumias and 
Nyando, respectively.  The findings in this study may differ from previous studies because 
the study participants were recruited from MOH clinics which primarily serve poorer women 
in Kenya (women with more resources often seek FP services from private clinics) and the 
large attrition. 
Given the predictors of discontinuation differed between the two districts in the 
primary analysis, we suggest a tailored approach be utilized for interventions aiming to 
increase contraceptive continuation.  Qualitative methods such as focus group discussions 
conducted with members of the intended target audience could be used to gather 
community-specific information for such interventions.  However, the findings from the 
sensitivity analyses indicated the opposite practice recommendation since no differences 
were found between the associations between the predictors and discontinuation in the two 
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districts when we applied our revised definition for discontinuation.  Nevertheless, we 
consider the primary analyses, since they represent the unaltered data, to be superior to the 
sensitivity analyses in this study.  Tailored intervention approaches are more costly in terms 
of time and resources when compared to universal approaches, and these costs need to be 
considered when deciding how to stretch limited FP funding. 
The results from both the primary and sensitivity analyses suggest that the rates of 
discontinuation differ between the two districts prior to implementation of the communication 
campaign.  According to the primary analysis Nyando has a slower rate of discontinuation 
compared to Mumias.  However, the results of the sensitivity analysis called into question 
the direction of this difference.  Unfortunately, over the course of this prospective study, loss 
to follow-up was substantially higher in Nyando (58%) compared to Mumias (37%).  
Moreover, the pattern of loss was different in the two districts, with Nyando losing a greater 
proportion of its respondents earlier in the study compared to Mumias.  This loss to follow-up 
was the result of a contractual dispute and has been resolved for the post-intervention 
fieldwork.  Nevertheless, the high and differential lost to follow-up during the pre-intervention 
influenced the findings presented in this paper and is clearly the study’s greatest limitation.  
While the truth probably lies some where in between the results from the primary and 
sensitivity analysis, given the interpretation from the two analyses differ, we consider the 
results from the primary superior since they represent the unaltered data. 
We conducted the follow-up interviews every three months or a few days after the 
study participants would have received their next injection should they desire re-injection.  
While we reminded women at every encounter that they did not have to continue using any 
contraceptive method to remain in the study, it is possible that the follow-up interviews 
influenced continuation by reminding women about their upcoming injections.  Thus, the 
data collection procedures may pose a threat to the external validity of this study.   
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This study had several strengths, most notably its inclusion of a comprehensive list 
of independent variables.  In addition to measuring those factors researchers included in 
previous studies of contraceptive continuation, this study also incorporated novel factors 
based on health behavior theory, using factor analytical techniques.  However, with the 
exception of the variable measuring nervousness of using contraception, we failed to find 
evidence of effect of these attitudinal and motivational factors on discontinuation.  It is 
possible that the effects of side effects related to contraceptive use, in particular DMPA, are 
so strong that it is difficult to detect effects from the attitudinal and motivational factors.  Or, 
perhaps differences were not detected because of reduced power due to the loss to follow-
up.  Another explanation could be related to the measures themselves.  While the items 
included in the factor analyses had face validity and displayed variability among the study 
participants, it is possible that they did not accurately measure the intended constructs.  The 
items were not subjected to prior rigorous psychometric testing.  In sum, the lack of 
evidence for the effect of the factors related to behavioral theories in this study does not 
mean that these factors do not affect discontinuation behavior.  Instead, the findings suggest 
we need to continue using health behavior theory to inform future research on this topic and 
build on the findings from this study by improving our measures of these constructs. 
A second strength of this study is the prospective longitudinal study design combined 
with the incorporation of time-dependent variables, which should reduce potential recall bias 
and decreased the threat to the internal validity of the study.  The findings from this study 
advance our understanding of contraceptive continuation behavior in western Kenya, which 
can be used to inform interventions designed to increase continuation rates in the region.  
This study contributed to the body of evidence highlighting the importance of side effects 
and health concerns on premature discontinuation of contraception—clearly these issues 
must be addressed more strongly in FP services. 
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Table 3.1:  Descriptive statistics (percentages) for time invariant variables by site (number of 
participants) 
Variable Mumias (N=436) Nyando (N=431) 
 Non-missing 
observations 
% with 
attribute 
Non-missing 
observations 
% with 
attribute 
Urban residence 436 41 430 29 
Luhya/Luo 434 92 430 90 
At least primary education 436 67 423 59 
Secondary education or more 436 24 423 38 
Christian 434 86 428 98 
Married at enrollment 434 89 428 88 
Previous modern contraceptive 
use 
436 22 431 23 
Does not want any more 
children (limiter) 
431 27 428 34 
Husband disapproves of 
contraceptive use 
422 17 398 21 
Experience a discontinuation 436 15 431 8 
Lost-to-follow up 436 37 431 58 
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Table 3.2:  Descriptive statistics (means) for time invariant variables by site (number of participants) 
Variable Mumias (N=436) Nyando (N=431) 
Non-
missing 
observa-
tions 
Mean Std Dev Non-
missing 
observa-
tions 
Mean Std Dev 
Age 436 25 6 431 25 6 
Number of living 
children 
427 3 2 417 3 2 
Number of 
methods 
discussed by 
provider during 
enrollment 
434 4 2 431 4 3 
Number of days 
participant plans 
to use 
injectables 
390 1577  1027 419 1840 2118 
Number of days 
of continuous 
use of modern 
method during 
study (max 294) 
436 212 73 431 201 75 
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Table 3.3:  Descriptive statistics (percentages) for time dependent variables by site (number of 
records) 
Variable Mumias (N=970) Nyando (N=876) 
 Non-missing 
observations 
% with 
attribute 
Non-missing 
observations 
% with 
attribute 
Change in marital status  968 7 873 4 
Contraception 
Experienced at least one side 
effect/health concern while 
using injectables 
956 39 868 30 
Fear of side effects/health 
concerns due to method 
841 42 729 33 
Feels very confident to use 
contraception to avoid 
pregnancy 
945 86 868 88 
Fertility intentions 
Wants a child in the next 2 
years or less 
858 16 826 13 
Wants a child in 2 or more 
years 
858 56 826 53 
Perceived quality of care 
Problem accessing injectables  872 16 778 13 
FP method of choice was 
available 
838 99 730 97 
Received method of choice  838 98 730 95 
Overall satisfied with care  835 92 725 97 
Felt there was enough privacy 
during the FP appointment 
840 50 725 83 
Very satisfied with provider 839 86 727 95 
Comfortable discussing  
questions or concerns with 
provider 
810 84 725 89 
All questions about FP method 
answered by provider 
831 57 727 64 
Very satisfied with the level of 
cleanliness at the facility 
852 83 731 89 
Willing to return to the same 
facility for next FP 
appointment 
849 99 722 98 
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Table 3.4:  Descriptive statistics (means) for time dependent variables by site (number of records) 
Variable Mumias (N=970) Nyando (N=876) 
Non-
missing 
observa-
tions 
Mean Std Dev Non-
missing 
observa-
tions 
Mean Std Dev 
Number of side 
effects experienced or 
health concerns 
reported 
956 1 1 868 1 1 
Frequency of 
exposure to FP 
information in the 
community during 
past three months 
(range 0-12) 
881 3 2 826 4 3 
Not nervous about 
using contraception 
(range 1-5) 
948 4 1 867 4 1 
Cost of FP services 
including 
transportation (in 
Kenyan Shillings) 
855 53 25 731 42 47 
Factors from exploratory factor analyses 
Motivations to avoid 
pregnancy – 
Husband/partner 
support of 
contraception 
965 0.10 0.72 876 0.04 0.70 
Motivations to avoid 
pregnancy – Self 
motivation to use 
contraception 
965 0.07 0.70 876 0.01 0.22 
Motivations to avoid 
pregnancy – Family 
support of 
contraception 
965 0.04 0.81 876 0.01 0.63 
Cohesive family 
planning expectations  
965 -0.03 0.76 876 -0.01 0.72 
Empowered decision 
making about 
woman’s health 
965 0.01 0.66 876 0.01 0.68 
Information to users 
about FP method 
858 -0.07 0.79 731 -0.09 0.71 
 
 
 87
Table 3.5:  Hypothesis 1 – Primary Analysis - Mumias 
Mumias District Parameter Estimate Std Error p-value 
Number of side effects 
experienced or health 
concerns reported 
0.35 0.16 0.029 
Cost of FP services 
including 
transportation  
-0.01 0.01 0.082 
Previous modern 
contraceptive use 
-0.93 0.23 <.0001 
Married at enrollment -0.21 0.22 0.349 
Not nervous about 
using contraception 
-0.20 0.06 0.001 
Felt there was enough 
privacy during the FP 
appointment 
-1.59 0.41 0.0002 
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Table 3.6:  Hypothesis 1 – Primary Analysis - Nyando 
Nyando District Parameter Estimate Std error p-value 
Number of side effects 
experienced or health 
concerns reported 
0.50 0.13 0.0001 
Cost of FP services 
including 
transportation  
0.005 0.001 0.0002 
Previous modern 
contraceptive use 
-0.17 0.23 0.446 
Married at enrollment -1.07 0.34 0.002 
Not nervous about 
using contraception 
-0.17 0.08 0.029 
Felt there was enough 
privacy during the FP 
appointment 
-0.86 0.57 0.151 
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Table 3.7:  Hypothesis 2 – Primary Analysis 
Variable  Difference 
(Mumias 
estimate – 
Nyando 
estimate) 
Std error of the 
difference 
Lower 
confidence 
bound  
Upper 
confidence 
bound  
Number of side 
effects 
experienced or 
health concerns 
reported 
-0.14 0.21 -0.54 0.26 
Cost of FP 
services including 
transportation  
-0.02 0.01 -0.03 -0.00 
Previous modern 
contraceptive use 
-0.76 0.32 -1.40 -0.12 
Married at 
enrollment 
0.86 0.41 0.06 1.65 
Not nervous 
about using 
contraception 
-0.03 0.10 -0.22 0.16 
Felt there was 
enough privacy 
during the FP 
appointment 
-0.73 0.71 -2.12 0.65 
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Figure 3.1:  Hypothesis 3 – Primary Analysis 
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Table 3.8:  Hypothesis 1 – Sensitivity Analysis - Mumias 
Mumias District Parameter Estimate Std Error p-value 
Number of side effects 
experienced or health 
concerns reported 
0.11 0.07 0.103 
Cost of FP services 
including 
transportation  
-0.00 0.00 0.553 
Previous modern 
contraceptive use 
-0.32 0.15 0.033 
Married at enrollment -0.26 0.13 0.050 
Not nervous about 
using contraception 
-0.04 0.06 0.500 
Felt there was enough 
privacy during the FP 
appointment 
-0.15 0.19 0.420 
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Table 3.9:  Hypothesis 1 – Sensitivity Analysis - Nyando 
Nyando District Parameter Estimate Std error p-value 
Number of side effects 
experienced or health 
concerns reported 
0.08 0.08 0.270 
Cost of FP services 
including 
transportation  
0.00 0.00 0.092 
Previous modern 
contraceptive use 
-0.29 0.12 0.013 
Married at enrollment -0.38 0.17 0.031 
Not nervous about 
using contraception 
-0.04 0.08 0.566 
Felt there was enough 
privacy during the FP 
appointment 
-0.38 0.24 0.121 
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Table 3.10:  Hypothesis 2 – Sensitivity Analysis 
Variable Difference 
(Mumias 
estimate – 
Nyando 
estimate) 
Std error of the 
difference 
Lower 
confidence 
bound 
Upper 
confidence 
bound 
Number of side 
effects 
experienced or 
health concerns 
reported 
0.02 0.10 -0.17 0.22 
Cost of FP 
services including 
transportation  
-0.00 0.00 -0.01 0.00 
Previous modern 
contraceptive use 
-0.03 0.19 -0.41 0.35 
Married at 
enrollment 
0.11 0.22 -0.32 0.54 
Not nervous 
about using 
contraception 
0.00 0.10 -0.19 0.19 
Felt there was 
enough privacy 
during the FP 
appointment 
0.23 0.31 -0.38 0.83 
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Figure 3.2:  Hypothesis 3 – Sensitivity Analysis 
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CHAPTER 4. Conclusion 
 
This dissertation used qualitative and quantitative research methods to explore 
reasons for discontinuation of contraceptive injectables in the western region of Kenya. The 
purpose of this dissertation was to provide the foundation for interpretation of the findings of 
a four-year prospective, quasi-experimental study being conducted to encourage the 
continued use of contraceptives by developing, implementing and evaluating a 
communication campaign intended to increase continuation rates among contraceptive 
injectable users in Nyando District, Kenya (results expected mid-2010).  The pre-intervention 
research in this dissertation focused on the developmental work and baseline information 
that is required to interpret the findings from the evaluation of the intervention study.   
Using qualitative methods in the form of focus group discussions, the first paper 
identified the reasons women in Nyando District Kenya discontinue using contraceptive 
injectables from the perspectives of current users and their salient referents.  The second 
paper used quantitative data from a prospective longitudinal study to describe the factors 
which predict the occurrence and timing of contraceptive discontinuation among first-time 
contraceptive injectable users still in need of family planning (FP) in the treatment (Nyando 
District) and comparison (Mumias District) sites before implementation of the communication 
campaign; and to determine if the rates and predictors of discontinuation differ between the 
study districts before implementation of the communication campaign.  
In the qualitative paper numerous reasons for disconintuation were identified.  These 
reasons were categorized as logistical, social, or medical.  Logistical reasons included 
commodity stock outs, and unecessary and sometimes incorrect provider and/or clinic 
restrictions which inhibit women from receiving injections.  Three clinic restrictions for
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injection and re-injection found in this research are parity, hypertension and menstruation 
requirements. 
Social reasons for premature discontinuation of injectables highlight that women in 
Nyando District do not always have control over the use and continued used of 
contraception because such decisions are often made by their husbands or other influential 
people in their community and household.  Much of the opposition salient references hold 
towards the use FP methods stem from a low level of knowledge regarding side effects. 
Cultural beliefs about gender, sexual behavior and fertility also have an important role in 
discontinuation behavior.  Participants suggest involving men in FP educational efforts might 
make them understand the advantages of FP, the potential side effects of injectables, and 
be more understanding if their wife experiences side effects. 
Medical reasons for discontinuation in this study were numerous and, similar to 
previous research, commonly reported side effects of injectables included weight gain and 
menstrual changes.  Participants also reported side effects and health-related fears that are 
not found in medical literature on injectables like back aches, infertility, delivering a 
deformed baby, high blood pressure and drowziness.  Educational and counseling efforts in 
this community should be tailored to address these community-specific concerns. 
While previous research has primarily focused on user and method-
related characteristics associated with discontinuation, less attention has been paid to the 
influence of other people on discontinuation.  The research presented in the first paper 
expands our understanding of discontinuation by examining social influences on 
discontinuation through incorporating the perspectives of salient reference groups, and 
demonstrates the power of such groups. 
The second paper used prospective, longitudinal data from first-time contraceptive 
injectables users to measure pre-intervention continuation rates and the factors that predict 
the timing and occurrence of discontinuation in the treatment (Nyando District) and 
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comparison (Mumias District) sites. The demographic characteristics of the study 
participants in the two districts appear similar for most of the variables examined.  
Surprisingly, approximately a third of participants in both districts say they do not want any 
more children yet participated in this contraceptive injectable study.  A practice 
recommendation derived from this finding is to help those desiring to limit childbearing to 
use longer acting or permanent methods. 
The majority of participants continued using injectables over the course of the study.  
Prospective 9-month discontinuation rates for first-time injectable users in this study were 
24% in Mumias and 15% in Nyando.  Nationally, 21% of injectable users discontinue use of 
the method within 12 months of starting, despite still having FP needs.  While the rates 
found in this study are not directly comparable to the 12-month discontinuation rate 
calculated retrospectively from calendar data in the 2003 Kenya Demographic and Health 
Survey, it is interesting to note that they are similar to the national rate. 
The following factors predicted discontinuation in Nyando District:  experiencing side 
effects or health concerns, being nervous about using contraception, not being married at 
study enrollment, and paying more for FP services.  In Mumias District the factors that 
predicted discontinuation were:  experiencing side effects or health concerns, being nervous 
about using contraception, no previous use of a modern FP method, and preferring more 
privacy during the FP appointment.  These findings can be used to target contraceptive 
continuation interventions to reach those most likely to discontinue prematurely in the 
region.  The associations between predictors and contraceptive discontinuation differed 
between the two districts, as did the rates of discontinuation.  The findings suggest a tailored 
approach be utilized for interventions aiming to increase continuation. 
The results from both the primary and sensitivity analyses in the second paper 
suggest that the rates of discontinuation differed between the two districts prior to 
implementation of the communication campaign.  The main objective of the pre-intervention 
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study was to determine if the rates of discontinuation differed between the treatment and 
comparison districts before implementation of the campaign so that the evaluation findings 
(expected mid-2010) would be more robust.  According to the primary analysis Nyando has 
a slower rate of discontinuation compared to Mumias.  However, the results of the sensitivity 
analysis are less clear and call into question the direction of this difference.  The high and 
differential loss to follow-up across the two districts in the pre-intervention study may have 
influenced the findings of the second paper and must be considered when interpreting and 
applying these findings to the evaluation of the intervention study.   
Loss to follow up in the present study is due to a contractual dispute with a field 
subcontractor that led to a break in data collection. However, the implications of this 
situation may be less detrimental than would be the case for the more common 
circumstance of loss due to  factors related to participants.  Typically, lost to follow-up 
occurs because study participants can not be located or refuse to participate in follow-up 
interviews.  In these latter situations participants who are lost to follow-up and those who 
remain in the study may differ from each other on factors that are related to the outcome of 
interest.  However, the contractual dispute which transpired in this pre-intervention study 
resulted in data collection being halted in the study districts at specific, but arbitrary, points 
of time.  This decreases the likelihood that the loss is systematic, and therefore not as likely 
to be strongly associated with the outcome (discontinuation). 
The most likely difference between those lost to follow-up in the two study districts 
and those who remained was urbanicity of study participants' residence (i.e., those lost were 
more likely to be from urban residences). Because of accessibility and ease of travel, it 
would take less time to stop data collection in urban areas compared to the more rural areas 
in the study districts, resulting in fewer urban follow-up interviews. To account for this 
difference, the urban/rural residence variable should be included in future survival models 
from these data. 
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The prospective longitudinal study design combined with the incorporation of time-
dependent variables employed in the second paper should have reduced potential recall 
bias and decreased the threat to the internal validity.  In addition, this research also 
incorporated novel attitudinal and motivational factors based on health behavior theory.  
With the exception of a measure of nervousness about using contraception, however, we 
failed to find evidence of an effect of these novel factors on discontinuation.  Several 
explanations are possible for this lack of association which are discussed in the second 
paper, and the absence of an association does not necessarily mean that these factors do 
not affect discontinuation behavior.  Since the findings in the second paper cannot be 
considered definitive and health behavior theories have been shown to predict numerous 
other health behaviors, we should continue using health behavior theory to inform future 
research on this topic and improve our measures of these constructs. 
The findings from both the qualitative and quantitative studies add to the body of 
evidence highlighting the importance of side effects and health concerns on premature 
discontinuation of contraception.  A programmatic recommendation stemming from these 
findings is that FP services more strongly address side effects and health concerns 
surrounding FP methods.  Both studies also indicate that interventions aimed at increasing 
contraceptive continuation be tailored to address community-specific concerns.  The first 
study demonstrates how the use of qualitative methods, in particular focus group 
discussions, can elicit community-specific concerns surrounding FP methods and highlights 
the need to extend data collection efforts beyond FP users to incorporate the perspectives 
of their salient referents.  It is important to note, however, that tailored intervention 
approaches are more costly in terms of time and resources when compared to universal 
approaches, and these costs need to be considered when deciding how to effectively spend 
limited FP funding. 
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The findings from this dissertation advance our understanding of contraceptive 
continuation behavior in western Kenya, which can be used to inform interventions designed 
to increase continuation rates in the region.  The findings may also inform continuation 
efforts in other locations around the world by suggesting methods to identify community-
specific reasons for discontinuation and encouraging researchers to apply health behavior 
theories to their study design and instruments.  Finally, this dissertation will contribute 
valuable information to interpretation and recommendations generated from evaluation of 
the intervention. 
Next steps 
Elements of the communication campaign  
The next phase of this research is to determine if a communication campaign can 
increase contraceptive continuation rates.  The formative research presented in the first 
paper of this dissertation was used to develop a communication campaign that addressed 
community-specific concerns and targeted current contraceptive users and their salient 
referents in Nyando District.  Six radio spots were developed using information learned 
through the focus group discussions.  One radio spot was targeted at the specific concerns 
of each of the following six groups:  current contraceptive injectable users, husbands of 
users, mothers-in-laws of users, community leaders, family planning providers, long-term 
injectable users.  For example, the radio spot targeting husbands addressed the specific 
side effects of injectables which were mentioned by husbands during the focus group 
discussions, including menstrual changes, weight changes and lower libido.  The radio spot 
also encouraged husbands to support their wives should they experience side effects.  The 
radio spot targeting community leaders focused on how family planning can reduce burden 
on community resources and attempted to dispel community-specific misconceptions of 
injectables such as infertility and birth defects.  All six radio spots were aired daily on a local 
radio station for ten months.   
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The communication campaign also consisted of a brochure for current users and 
three posters targeting current users, husbands and male community leaders, and family 
planning providers.  The brochure for current users discussed the advantages and side 
effects of injectables with attention to the specific concerns current users expressed during 
the focus group discussions, for example menstrual changes, weight changes and low 
libido. The content of each poster addressed community-specific concerns, as well.  For 
example, the poster for current users discussed menstrual changes associated with 
injectable use and encouraged users to return to the health clinic to switch contraceptive 
methods if bleeding changes were not tolerable.  The poster targeting family planning 
providers reminded providers to discuss community-specific misconceptions about 
injectables, such as infertility and birth defects, with their clients.  The campaign also 
included airing three additional radio spots (one targeting current users, husbands, and 
mothers-in-law) for a total of 60 times and three longer format, live radio shows that gave 
community members the opportunity to call in to ask questions to a guest speaker (a family 
planning expert and/or current family planning user).  These radio spots and features were 
based on the formative research findings and aired on a local radio station (a different 
station from the station mentioned above).  Finally, 195 community-health workers in 
Nyando District were trained on contraceptive injectables as part of the campaign.  On a 
larger scale, the intervention study serves as an example of how qualitative research 
methods, namely focus group discussions, can be used to elicit community-specific 
concerns, and how to use the information to develop and implement a targeted 
communication campaign for a community.  The next step is to determine if such a 
communication campaign can increase contraceptive continuation rates. 
Implications for evaluation of the communication campaign  
The analysis plan for the evaluation of the intervention study is to fit  the pre-
intervention and the post-intervention data from both districts together in a single Cox model 
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with terms for treatment (or district, since the two are masked), timing (pre- versus post-
intervention), and the interaction between treatment and timing.  Then we will define a 
contrast to test whether the discontinuation rates change differently between the Nyando 
and Mumias Districts, controlling for differences that exist in pre-intervention discontinuation 
rates.  However, given that assignment to treatment groups was not random, we cannot 
assume that unmeasured variables during the pre-intervention are unrelated to the outcome 
(discontinuation). In other words, treatment and district are confounded in this study which 
means that we cannot know for certain if the change in the outcome is due to pre-existing, 
unmeasured differences between the districts or the treatment.  If pre-existing, unmeasured 
differences between the districts are present, then this induces confounding bias in 
the study conclusions. This limitation is the disadvantage of quasi-experimental designs 
compared to randomized controlled trials.  Nevertheless, the inclusion of the pre-intervention 
measurement of discontinuation rates tells us about the magnitude of initial group 
differences.  The primary analysis presented in the second dissertation paper, for example, 
informed us that the two districts did have different pre-intervention discontinuation rates, 
with Nyando having a slower discontinuation rate compared to Mumias.  We will include this 
information in the model for the evaluation of the intervention as described above.   
One way to improve the study design would be to have multiple treatment and 
control districts which are randomized to either treatment or control conditions.  By having 
multiple districts in the study we could begin to assess a district effect because we would 
have variability across districts within treatment group and the randomization of districts to 
treatment conditions would eliminate bias caused by unmeasured confounders.  Of course, 
this study design would be more expensive than the study design used in this dissertation, 
especially for outcomes such as discontinuation that are measured over time.  However, 
researchers and funding agencies would have to decide if the cost associated with this 
improved design is worth the extra resources given the host of other public health priorities. 
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Implications for measurement 
Another future direction stemming from this research is to further refine 
measurement of motivational and attitudinal factors that may predict contraceptive 
continuation behavior.  The novel factors used in the second paper of this dissertation were 
not subjected to prior psychometric testing nor validation, despite use in other contexts.  
Without psychometric and validation information it is not possible to definitively determine 
whether associations between motivational/attitudinal factors and discontinuation exist.  It is 
important to determine if these factors influence discontinuation because they could be used 
by public health practitioners to target limited family planning resources to groups of women 
most at risk for pre-mature discontinuation.  Unfortunately, most public health funding 
mechanisms do not prioritize the development and validation of measures and scales. 
Considering both its strengths and limitations, the intervention study is an important 
step in addressing the public health problem of contraceptive discontinuation.  The 
intervention study, including the findings presented in this dissertation, will put us closer to 
understanding the complex factors that affect contraceptive discontinuation and closer to the 
goal of meeting family planning needs. 
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Appendix:  Description of independent variables 
 
The dichotomous, time-dependent variable experienced a side effect or report a health 
concern was constructed from the following two questions:  “Since your last interview 
approximately three months ago, did you experience any side effects or problems while 
using injectables?” (Response option: Yes/No) If respondent answered “No” to this question 
then she was coded "No" to the side effects/health concern variable.  If respondent 
answered “Yes” her response to the following question was evaluated:  “What side effects or 
problems did you experience using injectables?”  (Response option:  Circle all that are 
mentioned.) The respondent was coded “Yes” to the side effect/health concern variable if 
she mentioned any side effect or health concern.  A continuous, time-dependent variable 
was also constructed from this question by summing the number of unique side effects 
mentioned by the respondent.  
 
A dichotomous, time-dependent measure of fear of side effects/health concerns was 
constructed based on responses the question "What concerns do you have about using this 
method?"  If a respondent reports a fear of any side effect or health concern including fears 
not found in the medical literature to this question then she was coded "Yes" for the fear of 
side effects variable.  Otherwise, the respondent was coded "No" to this variable.   
 
A dichotomous, time invariant measure of husband’s disapproval was constructed with 
following question, “Do you think that your husband/partner approves or disapproves of 
couples using a contraceptive method to avoid pregnancy?”  (Approves/Disapproves) 
 
A continuous, time-dependent measure of cost of family planning services was 
constructed by summing the following questions:  "How much were you charged for the 
services you received at your most recent family planning appointment?" and "How much 
did you pay for one-way transportation to that appointment?" 
 
A dichotomous, time-dependent measure of access to injectables was constructed as 
follows:  Respondents were coded as not having access to injectables if they reported 
injectables were difficult or impossible to obtain when asked “What side effects or problems 
did you experience using injectables?”  (Response option:  Circle all that are mentioned.) 
during the interview when a discontinuation was reported OR if they reported “yes” to the 
following question: “Did you come more than once to get your most recent family planning 
appointment?”  Otherwise, respondents were coded as having access to injectables. 
 
Urban-rural residence (dichotomous; time invariant) was determined by asking 
respondents "Where do you currently live?"  The name of the town or neighborhood was 
recorded verbatim.  A dichotomous variable coded "urban" or "rural" was created based on 
the responses to this question with the assistance of in-country field staff. 
 
Age (ordinal in years; time invariant) was measured by asking "How old were you at your 
last birthday?" 
 
Education (categorical; time invariant) was constructed from the following two questions: 
"Have you ever attended school?"  (Response options:  Yes/No) and "What was the highest 
level of school you completed?"  (Response options:  Primary, Secondary, Post-secondary).  
Two dummy variables were created.  The first dummy variable was for primary school where 
the reference cell was no education.  Given the few responses for post-secondary school 
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this response option was combined with secondary school to form the second dummy 
variable where the reference cell was no education. 
 
Ethnicity (dichotomous; time invariant) was constructed by asking "Which ethnic group do 
you belong to?"  The vast majority of respondents were members of the predominate ethnic 
group in each of the study districts (Luo in Nyando District and Luhya in Mumias District) 
and therefore the responses were categorized into the dominant ethnic group in the district 
versus other. 
 
Religion (dichotomous; time invariant) was determined by asking "What religion are you?"  
The majority of respondents in both study districts were Christian and therefore the 
responses were categorized into Christian versus other religion. 
 
Income (continuous; time invariant) was measured with the question "How much household 
income does your household receive each month, counting all sources?"  This variable was 
log-transformed to rescale the variable so it would not overwhelm the survival analysis 
model. 
 
Number of living children (ordinal; time invariant) was determined by asking respondents 
"How many living children do you have?" 
 
Baseline marital status (dichotomous; time invariant) was determined by asking “Are you 
married”.  Respondents who said they were married during the baseline (enrollment) 
interview were coded as “Yes” to this variable and those who said they were not married 
were coded “No.” 
 
A dichotomous, time-dependent measure of the change in marital status was constructed 
by comparing the response to "Are you married?" between two consecutive interviews for 
each respondent.  If there is a change in marital status (either married to not married or vice 
versa) then the new variable was coded "Yes, change in marital status".  If marital status 
remained the same over consecutive interviews then the new variable was coded "No."  
 
A dichotomous; time invariant variable measuring previous modern contraception use 
was constructed by examining the question "Have you or your partner ever used or tried to 
use some method to delay or avoid a pregnancy before today?" (Response options:  
Yes/No) If the response to this question was "No" then the respondent was coded "did not 
previously use modern method" for the new variable.  If "Yes," the response to the next 
question, "What methods have you ever used or what have you done to avoid getting 
pregnant before today?", was considered.  If the respondent reported previous use of a 
modern method (defined according to the DHS definition) the respondent was coded 
“previously used modern method" for the new variable.  If the respondent reported using a 
traditional method in the past she was coded "did not previously use modern method" for 
this variable. 
 
A dichotomous, time-dependent measure of exposure to family planning (FP) 
information in the community was constructed by assessing responses to the following four 
questions: 
• In the last three months, have you heard advertisements on the radio about any of 
the following health topics? 
• In the last three months, have you seen advertisements on the television about any 
of the following health topics?  
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• In the last three months, did you hear any information about any of the following 
health topics during theatre performances?  
• In the last three months, have you read any information about any of the following 
health topics on a poster, billboard or in a pamphlet?  
 
Response options for these questions were:  Alcohol use/HIV/AIDS/Nutrition/Domestic 
violence/Malaria/Family planning/Birth spacing/Continuing to use a family planning 
method/Oral re-hydration for children. 
 
If respondents reported they were exposed to information about the following:  family 
planning, birth spacing, or continuing to use a family planning method for any one of these 
questions then the new FP exposure variable was coded "Yes" otherwise this variable was 
coded "No." A continuous, time-dependent variable was also constructed from these four 
questions by summing the number of affirmative responses each respondent reported being 
exposed to during past three months.  The possible scoring range was 0 (never exposed) to 
12 (exposed to all three FP topics through all four mediums) for this continuous variable. 
 
 A dichotomous, time invariant variable measuring fertility intentions (spacer vs. limiter) 
was constructed by categorizing respondents as a spacer or limiter based on their response 
to the following question, "Would you like to have (a/another) child, or would you prefer not 
to have any (more) children?" Respondents who said they want to have a/another child were 
categorized a "spacer" and respondents who said they want no more children were 
categorized a "limiter."  This question also included a response option for "undecided" and 
"don't know" responses because it was expected that many respondents would not be sure 
of their answer to this question.  Respondents who reported they were undecided or did not 
know were categorized as a "spacer" since conceptually these responses appeared more 
similar to spacer compared to the more definite response of limiters who stated they did not 
want any more children. 
 
Factor construction 
The aim of the first EFA was to construct time-dependent measures of motivations to 
avoid pregnancy.  The following 19 variables were entered into the EFA based on face 
validity:   
 
A continuous, time invariant measure of number of days participant plans to use 
injectables was constructed by asking the respondents “How long do you plan to continue 
using injectables?”  Participants could respond in days, months and/or years, however for 
analysis all responses were converted to years. 
 
An ordinal, time-dependent variable measuring current fertility intentions was constructed 
by asking the question, “How long would you like to wait from now before the birth of 
(a/another) child?  (Response options:  Less than 2 years/More than 2 years/No more 
children).  The response “No more children” was coded 3, the response “More than 2 years” 
was coded 2 and the responses “Less than 2 years” and “Soon” was coded 1.   
 
Husband’s fertility intentions (dichotomous, time-dependent) were measured with the 
question, “Does your husband/partner want to have another child within two years?” 
(Response options:  Yes/No)  “Don’t know” responses were combined with “Yes” responses. 
 
Problem if became pregnant (ordinal, time-dependent) was measured with the question, 
“In the next few weeks, if you discovered that you were pregnant, would that be a big 
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problem, a small problem, or no problem for you?” (Response options:  Big problem/small 
problem/no problem)  The response “Big problem” was coded 3, the responses “Small 
problem” and “Don’t know” was coded 2 and the responses “No problem” were coded 1. 
 
Confidence to use contraception (ordinal, time-dependent) was measured with the 
question, “How confident are you that you will be able to successfully use contraception to 
avoid pregnancy?”(Response options:  Very confident/somewhat confident/not very 
confident) 
 
Fourteen attitudinal variables (ordinal, time-dependent) were created from the question, 
“For the following statements, please say whether you strongly agree, moderately agree, 
neither agree or disagree, moderately disagree, or strongly disagree”: 
 
a.  I will use contraception to avoid becoming pregnant within the next 12 months. 
b.  My husband/partner agrees that I should continue utilizing contraception for the 
next 12 months 
c.  My husband/partner expects me to use contraception. 
d. My husband/partner opposes my using contraception. 
e.  My family expects me to use contraception. 
f. My family opposes my using contraception. 
g.  My husband/partner would be upset if I became pregnant. 
h.  My family would be upset if I became pregnant. 
i.  I am nervous about using contraception. 
j.  I am using contraception because there are negative consequence to getting 
pregnant now. 
 k.  I would feel anxious or guilty if I became pregnant now. 
 l.  Using contraception allows me to control when I get pregnant. 
 m.  Using contraception allows me to give better care to my family. 
n.  Using contraception allows me to pursue educational and/or employment 
opportunities. 
 
One variable, the number of days participant plans to use injections, was eliminated 
from the EFA to enable the model to converge and the model was re-run.  After examining 
the scree plot, three factors tapping motivation were retained.   
 
Three variables were eliminated from the EFA because they violated Thurstone's 
criteria for simple structure:  current fertility intentions, confidence to use contraception, and 
nervousness about using contraception.  The variables eliminated from the EFA were 
assessed individually in the bivariate analyses for their inclusion in the final survival model.  
For the current fertility intention variable, two dummy variables were created from the 
original question (“Less than 2 years” and “More than 2 years” where “No More Children” 
served as the reference cell) prior to including this item in the bivariate analyses. 
 
The EFA was re-run with the remaining15 variables.  The first factor was interpreted 
to measure perceived husband/partner’s support of contraceptive use (e.g., husband/male 
partner does not want to have another child within two years; husband/partner expects 
respondent to use contraception; and husband/partner would be upset if respondent 
became pregnant).  The second factor was interpreted to measure self-motivation to use 
contraception (e.g., respondent agrees that she will use contraception to avoid becoming 
pregnant within the next 12 months; is using contraception because there are negative 
consequences to getting pregnant now; and the use of contraception allows the respondent 
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to pursue education and/or employment opportunities).  The third factor was interpreted to 
measure perceived family support of contraceptive use (e.g., family expects respondent to 
use contraception; family would be upset if respondent became pregnant; and using 
contraception allows respondent to give better care to her family). 
 
The goal of the second EFA was to construct time-dependent measures of decision 
making power regarding contraceptive use and health care.  The following six variables 
were entered into the EFA based on face validity:   
 
An ordinal, time-dependent variable measuring family planning self determination was 
constructed from the question, “Would you say that using family planning is mainly your 
decision, mainly your husband’s/partner’s decision or did you both decide together?” 
(Response options:  Mainly respondent/Mainly husband/Joint decision/Other person)  The 
response “Mainly respondent” was coded 3, the response “Joint decision” was coded 2 and 
the responses “Mainly husband”, “Other”, and “Don’t know” were coded 1. 
 
An ordinal, time-dependent variable measuring frequency of talking to husband/partner 
about family planning was constructed from the question, “How often have you talked to 
your husband/partner about family planning in the past 3 months?”  (Response options:  
Never/Once or twice/More often) The response “More often” was coded 3, the response 
“Once or twice” was coded 2 and the responses “Never” were coded 1. 
 
An ordinal, time-dependent variable measuring similarity between husband and wife’s 
desired number of children was constructed from the question, “Do you think your 
husband/partner wants the same number of children that you want, or does he want more or 
fewer than you want?” (Response options:  Same number/more children/fewer children)  
The response “Fewer” was coded 3, the response “Same” was coded 2 and the responses 
“More” were coded 1. 
 
A dichotomous, time-dependent variable measuring woman’s empowerment in her sexual 
relationship was assessed with the question, “In general, if you disagree with your 
husband/partner, should you keep quite or speak up? (Response options:  Speak up/Keep 
quite) 
 
An ordinal, time-dependent variable measuring health care self determination was 
constructed from the question, “Who usually makes decisions about your health care?” 
(Response options:  Mainly respondent/Mainly husband/Joint decision/Other person)  The 
response “Mainly respondent” was coded 3, the response “Joint decision” was coded 2 and 
the responses “Mainly husband”, “Other”, and “Don’t know” were coded 1. 
 
An ordinal, time-dependent variable measuring number of children self determination 
was constructed from the question, “Who has the ultimate say in your house about the 
number of children you and your husband/partner should have?” (Response options:  Mainly 
respondent/Mainly husband/Joint decision/Other person)  The response “Mainly respondent” 
was coded 3, the response “Joint decision” was coded 2 and the responses “Mainly 
husband”, “Other”, and “Don’t know” were coded 1. 
 
The model converged; no variables were eliminated from this EFA.  After examining 
the scree plot, two factors were retained.  The first factor was interpreted to measure 
cohesive family planning expectations (e.g., greater frequency of talking to husband/partner 
about FP in the past three months; similarity between the husband and wife’s desired 
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number of children) while the second factor measured empowered decision-making about 
the woman’s health (e.g., respondent feels she should speak up if she disagrees with her 
husband/partner; respondent usually makes decisions about her health care; and 
respondent has the ultimate say about the number of children she has).   
 
The purpose of the last EFA was to construct time-dependent measures of perceived quality 
of care at the last FP appointment.  Twenty-one variables were entered into the EFA based 
on face validity. These variables included:  
 
A continuous, time invariant variable was constructed to represent the number of 
contraceptive methods discussed with respondent during enrollment by summing the 
responses from baseline question, "Which methods of family planning did the provider 
discuss with you today?" 
 
Availability of methods (dichotomous, time-dependent) was assessed by examining 
responses to the question, "Why didn’t you receive the method you wanted to get?"  This 
new variable was coded "method of choice unavailable" if respondent said, "Clinic did not 
have my method" or, “Clinic did not have my brand."  Otherwise, this variable was coded 
"method of choice available.” 
 
Received method of choice (dichotomous, time-dependent was constructed by comparing 
the response to the question, “What method did you want to receive when you came to your 
appointment that day?" to the question, "Which methods of family planning did you receive 
at this most recent appointment?" at each interview.  If the responses to these two questions 
are different then the variable was coded "did not receive method of choice."  If the 
responses are the same then the variable was coded "received method of choice."  
Respondents indicating they had no method preference were coded as having received her 
method of choice. 
 
Satisfied with provider (ordinal, time-dependent) was measured with the question, “Were 
you dissatisfied or satisfied with how you were treated by this provider? If dissatisfied, 
somewhat unsatisfied, or very unsatisfied?  If satisfied, somewhat satisfied or very 
satisfied?” (Response options:  Very satisfied/Somewhat satisfied/Neither/Somewhat 
unsatisfied/ Unsatisfied)  The response options for Neither, Somewhat unsatisfied, 
Unsatisfied, and Don’t know were combined due to low frequencies. 
 
The ordinal, time-dependent variable comfort level for asking questions was measured 
with the question, “Did you feel comfortable to openly discuss any of your questions or 
concerns with the provider? (Response options:  Yes/Somewhat/No)  Responses of “don’t 
know” were combined with the somewhat category. 
 
An ordinal, time-dependent variable assessing the degree to which all the respondents’ 
questions were answered during the FP visit was measured with the question, “Were all 
your questions about this method answered by the provider? (Response options:  Yes/No 
questions/No)  The responses “no questions” and “don’t know” were combined. 
 
Satisfied with care received (dichotomous, time-dependent) was measured with the 
question, “Overall, are you dissatisfied or satisfied with the care that you received at this 
appointment?” (Response options:  Satisfied/Dissatisfied)  The response “don’t know” was 
combined with “dissatisfied” responses. 
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Satisfied with cleanliness at the facility (ordinal, time-dependent) was measured with the 
question, “How satisfied were you with the level of cleanliness at the facility?” (Response 
options:  Very satisfied/Somewhat satisfied/Neither/Somewhat unsatisfied/ Unsatisfied)  The 
response options for Neither, Somewhat unsatisfied, Unsatisfied, and don’t know were 
combined due to low frequencies. 
 
Enough privacy at the clinic (dichotomous, time-dependent) was measured with the 
question, “Would you have preferred more privacy during the appointment?” (Response 
options:  Yes/No)   
 
Willingness to return to the clinic for next FP appointment (dichotomous, time-
dependent) was assessed with the question, "Where do you think you will go for your next 
family planning appointment?" If the respondent said she planned to return to the same 
facility this dichotomous variable was coded "Yes" otherwise it was coded "No." 
 
Seven variables assessing method specific information provided to users 
(dichotomous, time-dependent) was measured with the questions, “Did the provider give you 
information about the following: (Response options: Yes/No) 
a. Advantages of this contraceptive method 
b. Disadvantages of this method 
c. How to use this method 
d. When to return for your next appointment 
e. What to do if you miss a dose 
f. Possible side effects or problems related to this method 
g. What to do if you experience side effects or problems 
 
Provider assessed respondent’s prior experience with contraception (dichotomous, 
time-dependent) was measured with the question, “Did the provider ask you about your prior 
experiences with contraception?” (Response options:  Yes/No)   
 
Provider asked respondent which methods she preferred (dichotomous, time-
dependent) was measured with the question, “Did the provider ask you what method you 
prefer to use?” (Response options:  Yes/No)   
 
Travel time to clinic (continuous, time-dependent) was assessed by asking the question, 
“Thinking about your most recent visit to obtain a family planning method, how long did it 
take for you to arrive at the facility?”  This variable was measured continuously in minutes 
and log transformed to rescale the variable so it would not overwhelm the factor analysis 
model. 
 
Wait time in clinic (continuous, time-dependent) was assessed by asking the question, 
“After arriving, how long did you wait for your appointment?”  This variable was measured 
continuously in minutes and log transformed to rescale the variable so it would not 
overwhelm the factor analysis model. 
 
Ten variables (number of contraceptive methods discussed with respondent, 
availability of methods, received method of choice, satisfied with provider, comfort level for 
asking questions, respondents’ questions were answered, satisfied with care received, 
satisfied with cleanliness at the facility, enough privacy at the clinic, willingness to return to 
the clinic for next FP appointment) were eliminated from the EFA to enable the model to 
converge and the model was re-run.  After examining the scree plot, a single factor was 
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retained.  The factor was interpreted to measure information about the FP method given to 
the FP user by the provider (e.g., side effects or problems related to the FP method; 
advantages of the FP method; and disadvantages of the FP method).  The variables 
eliminated from the EFA were assessed individually in the bivariate analyses for their 
inclusion in the final survival model. 
